

1 UNITED STATES DISTRICT COURT  
2 FOR THE NORTHERN DISTRICT OF OHIO  
3 EASTERN DIVISION

4 \*\*\*\*\*

5 IN RE: NATIONAL

6 PRESCRIPTION OPIATE Case No.  
7 LITIGATION 1:17-MD-2804

8 APPLIES TO ALL CASES

9 Hon. Dan A. Polster

10 \*\*\*\*\*

11 HIGHLY CONFIDENTIAL

12 SUBJECT TO FURTHER CONFIDENTIALITY REVIEW

13 Videotaped Deposition of ANUPAM  
14 B. JENA, M.D., Ph.D., held at the offices of  
15 Morgan, Lewis & Bockius, LLP, One Federal  
16 Street, Boston, Massachusetts, commencing at  
17 11:09 a.m., on the 6th of June, 2019, before  
18 Maureen O'Connor Pollard, Registered  
19 Diplomat Reporter, Realtime Systems  
20 Administrator, Certified Shorthand Reporter.

21  
22 GOLKOW LITIGATION SERVICES  
23 877.370.3377 ph | 917.591.5672 fax  
24 deps@golkow.com

Page 2	Page 4
<p>1 APPEARANCES: FOR THE PLAINTIFFS:</p> <p>2</p> <p>3 BARON &amp; BUDD, P.C. BY: MARK PIFKO, ESQ. JAY LICHTER, ESQ. (Remotely) 15910 Ventura Boulevard, Suite 1600 Encino, California 91436 818-839-2325 mpifko@baronbudd.com jlichter@baronbudd.com</p> <p>7</p> <p>8 FOR PURDUE PHARMA: DECHERT LLP BY: MELANIE MACKAY, ESQ. (Remotely) 35 West Wacker Drive Chicago, Illinois 60601 312-646-5800 melanie.mackay@dechert.com</p> <p>13</p> <p>14 FOR CARDINAL HEALTH, INC.:</p> <p>15 WILLIAMS &amp; CONNOLLY LLP BY: MELINDA JOHNSON, ESQ. (Remotely) 725 Twelfth Street, N.W. Washington, DC 20005 202-434-5452 mjohnson@wc.com</p> <p>18</p> <p>19 FOR AMERISOURCEBERGEN DRUG CORPORATION: REED SMITH LLP BY: NEIL HLAWATSCH, ESQ. (Remotely) ANNE ROLLINS, ESQ. (Remotely) 1717 Arch Street Philadelphia, Pennsylvania 19103 215-851-8100 nhlawatsch@reedsmith.com arollins@reedsmith.com</p> <p>24</p>	<p>1 APPEARANCES (Continued):</p> <p>2</p> <p>3 FOR JANSSEN and JOHNSON &amp; JOHNSON DEFENDANTS:</p> <p>4 O'MELVENY &amp; MYERS LLP BY: CAMERON BAGHAI, ESQ. (Remotely) 610 Newport Center Drive Newport Beach, California 92660 213-430-8117 cbaghai@omm.com</p> <p>7</p> <p>8 FOR HBC SERVICE, INC.:</p> <p>9 MARCUS &amp; SHAPIRA LLP BY: BENJAMIN KIFT, ESQ. (Remotely) One Oxford Centre, 35th Floor 301 Grant Street Pittsburgh, Pennsylvania 15219-6401 412-338-4690 kift@marcus-shapira.com</p> <p>14</p> <p>15 FOR RITE AID:</p> <p>16 MORGAN, LEWIS &amp; BOCKIUS LLP BY: ELISA P. MCENROE, ESQ. JOHN MALOY, ESQ. JOHN P. LAVELLE, JR., ESQ. (Remotely) 1701 Market Street Philadelphia, Pennsylvania 19103-2921 215-963-5000 elisa.mcenroe@morganlewis.com john.maloy@morganlewis.com</p> <p>21</p> <p>22 VIDEOGRAPHER: Robert Martignetti</p> <p>24</p>
Page 3	Page 5
<p>1 APPEARANCES (Continued):</p> <p>2</p> <p>3 FOR DISCOUNT DRUG MART, INC.:</p> <p>4 CAVITCH FAMLO &amp; DURKIN, CO., LPA BY: ROBERT WEST, ESQ. (Remotely) 1300 E. 9th Street Cleveland, Ohio 44144 216-621-7860 rwest@cavitch.com</p> <p>7</p> <p>8 FOR WALGREENS: BARTLIT BECK LLP BY: LESTER HOUTZ, ESQ. (Remotely) 1801 Wewatta Street Denver, Colorado 80202 303-592-3197 lester.houtz@bartlitbeck.com</p> <p>13</p> <p>14 FOR H.D. SMITH:</p> <p>15 BARNES &amp; THORNBURG LLP BY: ALYSSA HUGHES, ESQ. (Remotely) 11 South Meridian Street Indianapolis, Indiana 46204 317-261-7881 alyssa.hughes@btlaw.com</p> <p>18</p> <p>19 FOR WALMART: JONES DAY BY: STEVEN N. GEISE, ESQ. 4655 Executive Drive, Suite 1500 San Diego, California 92121-3134 858-314-1170 sngaise@jonesday.com</p> <p>24</p>	<p>1 INDEX</p> <p>2 EXAMINATION PAGE</p> <p>3 ANUPAM B. JENA, M.D., Ph.D. 9</p> <p>4 BY MR. PIFKO 177</p> <p>5 BY MS. MCENROE</p> <p>6</p> <p>7</p> <p>8 E X H I B I T S</p> <p>9 NO. DESCRIPTION PAGE</p> <p>10 1 Appendix B to expert report, List of Expert Testimony for Dr. Jena..... 65</p> <p>11 2 Series of timesheets..... 80</p> <p>12 3 Series of invoices from Analysis Group..... 110</p> <p>14</p> <p>15 4 May 10, 2019 Expert Report of Dr. Anupam B. Jena, MD, PhD..... 131</p> <p>16 5 Appendix E to expert report, falsification analysis of Distribution of Opioids and Common Non-Controlled Drugs..... 140</p> <p>18</p> <p>19 6 Appendix D to expert report, Summary of Plaintiff Experts Mentioning "Rite Aid"..... 144</p> <p>20</p> <p>21 7 Appendix C to expert report, Materials Considered..... 154</p> <p>22 8 Appendix A to expert report, Curriculum Vitae..... 166</p> <p>23</p> <p>24 9 Analysis Group Affiliate Status Report..... 167</p>

<p style="text-align: right;">Page 6</p> <p>1</p> <p>2 10 Plaintiffs' Notice of Oral</p> <p>3 Videotaped Expert Deposition..... 171</p> <p>4</p> <p>5</p> <p>6</p> <p>7</p> <p>8</p> <p>9</p> <p>10</p> <p>11</p> <p>12</p> <p>13</p> <p>14</p> <p>15</p> <p>16</p> <p>17</p> <p>18</p> <p>19</p> <p>20</p> <p>21</p> <p>22</p> <p>23</p> <p>24</p>	<p style="text-align: right;">Page 8</p> <p>1 Bockius on behalf of Rite Aid of</p> <p>2 Maryland, Inc. doing business as</p> <p>3 Mid-Atlantic Customer Support Center,</p> <p>4 and here as well defending the</p> <p>5 witness. I have my colleague John</p> <p>6 Maloy with me as well.</p> <p>7 MR. GEISE: Steve Geise from</p> <p>8 Jones Day on behalf of Walmart.</p> <p>9 MR. PIFKO: And then people on</p> <p>10 the phone, if you can say your name,</p> <p>11 your firm, and who you represent, I</p> <p>12 would appreciate it.</p> <p>13 MR. BAGHAI: This is Cameron</p> <p>14 Baghai from O'Melveny &amp; Myers</p> <p>15 representing the Johnson &amp; Johnson and</p> <p>16 Janssen defendants.</p> <p>17 MR. HLAWATSCH: This is Neil</p> <p>18 Hlawatsch of Reed Smith for</p> <p>19 AmerisourceBergen Drug Corporation.</p> <p>20 MR. WEST: This is Robert West</p> <p>21 from Cavitch representing Discount</p> <p>22 Drug Mart.</p> <p>23 MS. HUGHES: Alyssa Hughes from</p> <p>24 Barnes &amp; Thornburg on behalf of H.D.</p>
<p style="text-align: right;">Page 7</p> <p>1 P R O C E E D I N G S</p> <p>2</p> <p>3 THE VIDEOGRAPHER: We are now</p> <p>4 on the record. My name is Robert</p> <p>5 Martignetti. I'm a videographer for</p> <p>6 Golkow Litigation Services.</p> <p>7 Today's date is June 6th, 2019,</p> <p>8 and the time is 11:09 a.m.</p> <p>9 This video deposition is being</p> <p>10 held in Boston, Massachusetts, In Re:</p> <p>11 National Prescription Opiate</p> <p>12 Litigation.</p> <p>13 The deponent is Anupam Jena,</p> <p>14 MD, PhD.</p> <p>15 The court reporter is Maureen</p> <p>16 Pollard.</p> <p>17 Will counsel please identify</p> <p>18 themselves.</p> <p>19 MR. PIFKO: Good morning. Mark</p> <p>20 Pifko from Baron &amp; Budd Los Angeles on</p> <p>21 behalf of plaintiffs and the executive</p> <p>22 committee.</p> <p>23 MS. MCENROE: Good morning.</p> <p>24 Elisa McEnroe from Morgan, Lewis &amp;</p>	<p style="text-align: right;">Page 9</p> <p>1 Smith.</p> <p>2 MS. MACKAY: Melanie MacKay</p> <p>3 from Dechert on behalf of Purdue.</p> <p>4 MS. JOHNSON: Melinda Johnson</p> <p>5 of Williams &amp; Connolly on behalf of</p> <p>6 Cardinal Health.</p> <p>7 MR. KIFT: Benjamin Kift of</p> <p>8 Marcus &amp; Shapira on behalf of HBC.</p> <p>9 THE VIDEOGRAPHER: The court</p> <p>10 reporter will now swear in the</p> <p>11 witness.</p> <p>12</p> <p>13 ANUPAM B. JENA, M.D., Ph.D.,</p> <p>14 having been duly identified and sworn, was</p> <p>15 examined and testified as follows:</p> <p>16 EXAMINATION</p> <p>17 BY MR. PIFKO:</p> <p>18 Q. Good morning. My name is Mark</p> <p>19 Pifko. We just met for the first time off</p> <p>20 the record a few minutes ago. I'm going to</p> <p>21 be asking you some questions today, okay?</p> <p>22 A. Perfect.</p> <p>23 Q. All right. First thing, can</p> <p>24 you state and spell your name for the record?</p>

Page 10

1 A. Sure. My name is Anupam Jena.  
 2 A-N-U-P-A-M, last name is Jena, J-E-N-A.  
 3 Q. All right. And you've just  
 4 been administered the oath, so you understand  
 5 that your testimony here is under penalty of  
 6 perjury?  
 7 A. Yes, I do.  
 8 Q. Okay. And that means that if  
 9 you lie or are intentionally misleading or  
 10 dishonest, you could be subject to penalties  
 11 from the court.  
 12 Do you understand that?  
 13 MS. MCENROE: Objection to  
 14 form.  
 15 A. I understand that.  
 16 BY MR. PIFKO:  
 17 Q. Okay. Is there any reason why  
 18 you're not able to provide truthful and  
 19 accurate testimony today?  
 20 A. No, there's no reason.  
 21 Q. Are you taking any medications  
 22 or undergoing any treatment that would impair  
 23 your memory?  
 24 A. No.

Page 11

1 Q. Okay. Is there any reason that  
 2 you can think of why your deposition should  
 3 not proceed today?  
 4 A. No.  
 5 Q. So I'm sure that counsel went  
 6 over the ground rules of the deposition  
 7 before with you so we don't have to waste a  
 8 lot of time doing that, but if you have a  
 9 question, you don't understand something I  
 10 say, please let me know. If not, I'll assume  
 11 that you understand the question. Okay?  
 12 A. Perfect. I'll do that.  
 13 Q. And then just make sure you  
 14 give audible responses because the court  
 15 reporter can't take down shrugs of the  
 16 shoulders and nods of the heads. And then  
 17 don't say uh-huh or uh-uh, because on the  
 18 written record, it looks the same. Okay?  
 19 A. Of course. Thank you.  
 20 Q. So have you been deposed  
 21 before?  
 22 A. I have.  
 23 Q. How many times?  
 24 A. Three times.

Page 12

1 Q. Three times.  
 2 When was the most recent time  
 3 that you were deposed?  
 4 A. The most recent time I was  
 5 deposed was probably two to three months ago.  
 6 Q. What was that in connection  
 7 with?  
 8 A. That was a litigation matter  
 9 involving two pharmaceutical companies.  
 10 Q. How about the time before that?  
 11 A. The time before that, probably  
 12 four or five months before that.  
 13 Q. So this is in the last -- that  
 14 both of these were in the last year?  
 15 A. That's correct.  
 16 Q. You have three matters listed  
 17 in your appendix. So the first one is the  
 18 antitrust litigation. Is that what -- when  
 19 was the most -- was that the most recent?  
 20 MS. MCENROE: Counsel, are you  
 21 able to give the witness what you're  
 22 looking at so we can all be looking at  
 23 the same page?  
 24 MR. PIFKO: We'll get there.

Page 13

1 A. I mean, if you have a copy of  
 2 the report, I can walk through and make sure  
 3 I'm with you.  
 4 BY MR. PIFKO:  
 5 Q. You listed three matters that  
 6 you provided prior testimony in --  
 7 A. So the --  
 8 Q. -- that's all I'm asking.  
 9 A. -- the first one  
 10 chronologically is a Lamictal antitrust  
 11 matter.  
 12 The second one, I believe, or  
 13 the third one, is Momenta/Sandoz versus  
 14 Amphastar.  
 15 And the one in between I can't  
 16 recall without looking at the actual sheet.  
 17 Q. And so which was the one that  
 18 you most recently testified in?  
 19 A. The most recent one was the  
 20 Momenta/Sandoz/Amphastar, I believe, but it  
 21 would be --  
 22 Q. Okay.  
 23 A. -- helpful to look at the  
 24 actual.

<p style="text-align: right;">Page 14</p> <p>1 Q. Okay. And then six months or 2 so ago was -- which matter was that? 3 A. I'd have to look at the 4 actual -- 5 Q. Okay. 6 A. -- sheet. I'm involved in many 7 different matters, and so it's hard to keep 8 track of what I've done what and when. 9 Q. Okay. And then you testified a 10 third time as well? 11 A. I've been involved in two 12 depositions and one arbitration. I'm not 13 making a distinguish -- I'm not -- 14 Q. Okay. 15 A. -- distinguishing between those 16 two, but there may be a legal distinction 17 that I'm not aware of. 18 Q. Okay. So you testified twice 19 in a proceeding -- in connection with a 20 proceeding that was pending in a court? 21 A. Correct. 22 Q. And then once in connection 23 with a proceeding that was in an arbitration? 24 A. Correct.</p>	<p style="text-align: right;">Page 16</p> <p>1 MS. MCENROE: Objection to 2 form. 3 A. I have not served any -- as a 4 consulting expert in any other cases. 5 BY MR. PIFKO: 6 Q. You understand that you've 7 provided a report in this matter for Rite 8 Aid, is that correct? 9 A. That is correct. 10 Q. Okay. And you're -- are you 11 providing consulting work for them as well? 12 MS. MCENROE: Objection to 13 form. 14 A. I have been involved in some 15 consulting work prior to the production of my 16 report. 17 BY MR. PIFKO: 18 Q. Okay. And -- but that's in 19 connection with the opioid litigation? 20 A. That is correct. 21 Q. So in the opioid litigation, 22 you're serving as a testifying and a 23 consulting expert for Rite Aid, correct? 24 MS. MCENROE: Objection to</p>
<p style="text-align: right;">Page 15</p> <p>1 And the arbitration one, I'm 2 now jogging my memory, was Ranbaxy 3 Pharmaceuticals, and that was a contract 4 dispute. 5 Q. And when did you provide 6 testimony in connection with that matter? 7 A. Sometime in 2018, I believe. 8 Q. And you've never testified in 9 the history of your life before that? 10 A. Just the three matters that you 11 see there. 12 Q. Okay. Have you served as a 13 testifying expert in any other matters 14 besides those three matters? 15 MS. MCENROE: Objection to 16 form. 17 A. The only three matters that 18 I've served as a testifying expert in are 19 those three that are listed there. 20 BY MR. PIFKO: 21 Q. Okay. Have you served as a 22 consulting expert in connection with any 23 litigation, whether it's pending in a court 24 or arbitration?</p>	<p style="text-align: right;">Page 17</p> <p>1 form. 2 A. In the opioid litigation, I 3 serve as a test -- I'm serving as a 4 testifying expert. All the work that's 5 embodied in my report was the work that I 6 did. 7 There's a separate consulting 8 work that Rite Aid has been doing with a 9 company called Analysis Group that supported 10 my report. I have been peripherally involved 11 in that. But the bulk of my involvement with 12 Rite Aid, the vast majority, in fact, has 13 been related to the report that you have in 14 front of you. 15 BY MR. PIFKO: 16 Q. So other than those three 17 matters, there's no other testifying or 18 consulting work, setting aside the opioid 19 litigation, that you've ever done in your 20 career, is that correct? 21 MS. MCENROE: Objection to 22 form. 23 A. Can you clarify that question? 24 BY MR. PIFKO:</p>



Page 18

1 Q. Just, I want to -- I think you  
2 already answered, but I want to be crystal  
3 clear, that for litigation, whether it be in  
4 a court or arbitration, other than those  
5 three matters and this matter, you've never  
6 served as a consulting or testifying expert,  
7 correct?

8 MS. MCENROE: Objection to  
9 form.

10 A. That is correct.

11 BY MR. PIFKO:

12 Q. Okay. Have you provided  
13 consulting services outside the context of a  
14 litigation-type dispute?

15 A. I have.

16 Q. Okay. When did you first start  
17 doing consulting work?

18 A. I would say probably 2005,  
19 2006, sometime in that time frame.

20 Q. I want to talk a little bit  
21 about your work history.

22 So did you go straight through  
23 like high school, college, graduate school?  
24 Did you take any breaks?

Page 19

1 A. I have not taken any breaks.

2 Q. Okay.

3 A. I finished college in, I  
4 believe, 19 -- I started college in 1996,  
5 went to MIT, finished in 2000, and have been  
6 going straight since then.

7 Q. Okay. Let's just quickly go  
8 through the degrees and the years that you  
9 graduated, and the institutions.

10 So when did you graduate high  
11 school?

12 A. 1996.

13 Q. And where did you go to high  
14 school?

15 A. I went to a school called the  
16 Governor's School for Government and  
17 International Studies. It's in Richmond,  
18 Virginia.

19 Q. Did you have any sort of  
20 specialization there?

21 A. No, just high school.

22 Q. And then you graduated from  
23 undergrad from where?

24 A. MIT.

Page 20

1 Q. Okay. What year?

2 A. 2000.

3 Q. What was your degree?

4 A. I had two degrees, one in  
5 biology and one in economics.

6 Q. Did you attend anywhere  
7 in-between high school and MIT, or you went  
8 to MIT?

9 A. I went straight to MIT.

10 Q. After you finished MIT, where  
11 did you go?

12 A. After I finished MIT, I went to  
13 University of Chicago.

14 Q. Did you get a degree from  
15 there?

16 A. I got two degrees from there.  
17 I got an MD, which is a medical doctorate,  
18 and then a PhD in economics.

19 Q. What year was that?

20 A. I started in University of  
21 Chicago in June of 2000, I believe, and I  
22 left Chicago, University of Chicago, in June  
23 of 2009.

24 Q. Did you go to any other schools

Page 21

1 after that?

2 A. No. That was the end of my  
3 formal education.

4 Q. You didn't do any postgraduate  
5 programs or anything like that?

6 A. You mean like a post-doc, is  
7 that what you're --

8 Q. Right.

9 A. -- referring to?

10 So between 2000 -- I'm just  
11 going to walk you through the history because  
12 it's a little bit complicated.

13 So I started in June of 2000, I  
14 took anatomy. In September of 2000, I  
15 started in the economics department at the  
16 University of Chicago. I did the course work  
17 for 2000 to 2002. In that time, I also took  
18 medical school courses as well.

19 From 2002 to 2004, I went back  
20 to medical school full-time, so two years of  
21 medical school, '02 to '04. From '04 to '06,  
22 I went back to my PhD in economics, and I  
23 completed my dissertation during that period.  
24 And I received a PhD from the econ department

Page 22

1 in June of 2006, I think.  
 2 From 2006 to 2007, I went to  
 3 UCLA in the RAND Corporation, where, on my  
 4 CV, it -- I'm not sure what it would be  
 5 listed at. I can take a look at it if you  
 6 have a copy for me. But it's a post-doc of  
 7 sorts, because I had just finished my PhD and  
 8 so I was doing some postdoctoral work at UCLA  
 9 in the RAND Corporation. And that was a  
 10 one-year engagement.

11 I returned back to University  
 12 of Chicago, I believe, in June of 2007 to  
 13 complete the final two years of medical  
 14 school, and I finished in 2009.

15 From 2009 to 2012, I was a  
 16 resident, an intern and resident at  
 17 Massachusetts General Hospital, which is one  
 18 of the Harvard teaching hospitals. It's very  
 19 close to here. During that time, I might  
 20 have been doing some postdoctoral work.

21 Again, I don't know what it  
 22 says on the CV, but I was probably doing  
 23 postdoctoral work ongoing with individuals  
 24 from the University of Chicago and from

Page 23

1 RAND/UCLA from my time there in the '06-'07  
 2 period.

3 Q. Okay.

4 A. I hope that clarifies for you.

5 Q. No, that's helpful. Thank you.

6 A. Perfect. Okay.

7 Q. So you said you first served as  
 8 a consultant in 2005-2006?

9 A. That would have been the first  
 10 time I did consulting work.

11 Q. Okay. What I want to ask you  
 12 is, excluding like summer jobs, mowing lawns,  
 13 or something like -- I'm not sure you did  
 14 anything like that.

15 A. I've done that.

16 Q. Okay. Was that your first real  
 17 job basically?

18 MS. MCENROE: Objection. Form.

19 A. That's a vague -- what do you  
 20 mean by "first job"?

21 BY MR. PIFKO:

22 Q. Well, what I'm trying to get at  
 23 is like --

24 A. For --

Page 24

1 Q. -- where was the first time you  
 2 had a job that you felt like was like a real  
 3 career job that you had?

4 MS. MCENROE: Objection to  
 5 form.

6 A. The first time I had a job, I'd  
 7 say, would be 2009 when --

8 BY MR. PIFKO:

9 Q. Okay.

10 A. -- I entered residency. I  
 11 mean, so I was a graduate student, I was a  
 12 medical student, and it's very common for  
 13 graduate students to do research assistant  
 14 work, and that's what I was doing, I was a  
 15 research assistant.

16 I'm calling it consulting  
 17 because the income was not coming from the  
 18 university, whereas a traditional research  
 19 assistant who is supporting a professor might  
 20 get paid from a grant that the university --  
 21 or that the professor has through the  
 22 university, so that's why I'm labeling it as  
 23 consulting. It wouldn't be a job in the way  
 24 that -- it wasn't a full-time job, let's put

Page 25

1 it that way.

2 My full-time work from an  
 3 employment perspective began in 2009 when I  
 4 finished res -- when I finished medical  
 5 school and began as an intern at Mass General  
 6 Hospital.

7 Q. Okay. So the research  
 8 assistant consulting work that you did, was  
 9 that just a one-off thing, or were there  
 10 several projects that you worked on?

11 MS. MCENROE: Objection to  
 12 form.

13 A. There was one project in,  
 14 again, I'm saying 2005-2006, I don't know the  
 15 exact date. There was some work that I did  
 16 then probably from 2000 -- let's call it 2006  
 17 until 2012, which is when I finished my  
 18 residency. I had probably several projects  
 19 that I worked on over that six to seven-year  
 20 period.

21 BY MR. PIFKO:

22 Q. The first project you can  
 23 remember in 2005-2006, who funded that?

24 A. The first project was funded by

Page 26

1 a company called Genentech.

2 Q. What was the nature of that  
3 work?

4 A. The nature of that work was an  
5 economic evaluation of the war on cancer. I  
6 actually can point it to you in my CV. But  
7 the basic idea behind the project was that  
8 there had been very little investigation as  
9 to the changes in survival over time of  
10 patients who are affected with cancer in this  
11 country, and what I wanted to do was  
12 understand, well, how has survival changed  
13 for people who have cancer, and what's the  
14 economic value of those gains in cancer  
15 survival.

16 Q. And then the next consulting  
17 job that you did, I'm talking about in this  
18 period from 2006 to 2012 that you just  
19 described where you're serving as a research  
20 assistant type of work, what was the next job  
21 after the Genentech work?

22 MS. MCENROE: Objection to  
23 form.

24 A. It's hard for me to know. I

Page 27

1 mean, a lot of the work that I did during  
2 that period was related to thinking about the  
3 economic value of medical innovations,  
4 particularly with respect to cancer care.

5 BY MR. PIFKO:

6 Q. Can you remember any of the  
7 other companies who funded projects that you  
8 worked on during that 2006 to 2012 time  
9 period?

10 MS. MCENROE: Objection to  
11 form.

12 A. Not specifically. I mean, I  
13 can tell you the companies that I've worked  
14 with ever that, you know --

15 BY MR. PIFKO:

16 Q. We'll get there.

17 A. Yeah.

18 Q. I just want to --

19 A. Yeah.

20 Q. -- narrow things.

21 A. Yeah. It's hard to pinpoint  
22 the time periods exactly.

23 Q. Okay. So sitting here today,  
24 there's no other -- you can't -- other than

Page 28

1 Genentech, you can't remember any other  
2 specific company who funded research that you  
3 were working on during 2006 to 2012?

4 MS. MCENROE: Objection to  
5 form.

6 A. What I can say is that I  
7 suspect that there were other companies that  
8 I was working with during that period, I just  
9 can't tell you exactly which ones.

10 The reason I remember the  
11 Genentech one in particular was, A, because  
12 it was my first time doing it, and B, because  
13 the work was pretty impactful. The White  
14 House office of the report of the president  
15 featured the work about the economic value of  
16 the war on cancer, the Federal Reserve Bank  
17 chair at that time, Ben Bernanke, described  
18 the work. So it's left an impression in my  
19 memory. Subsequent projects, I think it's  
20 hard for me to remember who exactly was  
21 involved, but there are probably other  
22 companies that I've worked with during that  
23 time.  
24

Page 29

1 BY MR. PIFKO:

2 Q. Okay. And then from 2009 to  
3 2012, you were a resident as well?

4 A. That's correct.

5 Q. Okay. And you earned some  
6 income associated with that?

7 A. That's correct.

8 [REDACTED]  
9 [REDACTED]  
10 [REDACTED]  
11 [REDACTED]  
12 [REDACTED]  
13 [REDACTED]  
14 [REDACTED]  
15 [REDACTED]  
16 [REDACTED]  
17 [REDACTED]  
18 [REDACTED]  
19 [REDACTED]  
20 [REDACTED]  
21 [REDACTED]  
22 [REDACTED]  
23 [REDACTED]  
24 [REDACTED]



Page 30

[REDACTED]

Page 32

[REDACTED]

Page 31

[REDACTED]

Page 33

[REDACTED]

Page 34

1 [REDACTED]  
2 [REDACTED]  
3 [REDACTED]  
4 [REDACTED]  
5 [REDACTED]  
6 [REDACTED]  
7 [REDACTED]  
8 BY MR. PIFKO:  
9 Q. Do you sit on any boards of any  
10 companies?  
11 A. No, I do not.  
12 Q. Do you own any stock of any  
13 pharmaceutical companies?  
14 A. I only own mutual funds.  
15 Q. Do you know if your -- you're  
16 married, you said?  
17 A. Yes, sir.  
18 Q. Do you know if your wife owns  
19 any stock in any pharmaceutical companies?  
20 A. No. She only has the same  
21 mutual funds that I do.  
22 Q. Is she in the medical field as  
23 well?  
24 A. Yes.

Page 35

1 Q. What does she do?  
2 A. She's a musculoskeletal  
3 radiologist.  
4 Q. She just works in the clinical  
5 setting?  
6 A. She actually works about  
7 half/half, half clinical/half research. Let  
8 me be clear. She works half clinical,  
9 one-quarter research, one-quarter quality and  
10 safety.  
11 Q. Where does she work?  
12 A. She works at Brigham & Women's  
13 Hospital.  
14 Q. And so she just has different  
15 roles within the hospital?  
16 A. That's correct.  
17 Q. That's in the Boston area?  
18 A. That's correct.  
19 Q. Let's talk about the consulting  
20 work that you've done from 2012 to 2017,  
21 okay?  
22 So in 2012 you finished your  
23 residency, correct?  
24 A. That's correct.

Page 36

1 Q. And then you moved into an  
2 academic position at Harvard?  
3 A. Yes.  
4 Q. When did you start the Harvard  
5 position?  
6 A. I would say June or July, 2012.  
7 Q. And then you also maintained a  
8 role doing clinical work at the hospital,  
9 though --  
10 A. Yes.  
11 Q. -- the same hospital where you  
12 did your residency?  
13 A. Exact same hospital, yes.  
14 Q. And then you started doing some  
15 more detailed consulting work?  
16 MS. MCENROE: Objection to  
17 form.  
18 A. I did the same type of  
19 consulting work that I had done prior, and a  
20 little -- again, a little bit during, during  
21 residency, and I continued doing that kind of  
22 work.  
23 BY MR. PIFKO:  
24 Q. Okay. But you devoted a little

Page 37

1 bit more time to that?  
2 A. I devoted a little bit more  
3 time to that, that's correct.  
4 Q. Thinking back to 2012, what's  
5 the first consulting job you can remember?  
6 A. I can't remember the specific  
7 job. I could -- if it's helpful to you, I  
8 could talk about the types of projects I do.  
9 But in terms of what consulting arrangement  
10 or what consulting project I had done in 2012  
11 versus 2013 versus 2014, it would be hard for  
12 me to parse it out for you.  
13 Q. Okay. Let's do this then. Can  
14 you identify any companies that have hired  
15 you to do consulting from 2012 to 2017?  
16 A. Sure.  
17 MS. MCENROE: Objection to  
18 form.  
19 A. That's easy to do. I do most  
20 of my consulting work through a company  
21 called Precision Health Economics, I'll  
22 abbreviate it as PHE. And that's the same  
23 group that I've been doing work with from  
24 2005, 2006. And through that company, I've

Page 38

1 worked with companies like Amgen, Novartis,  
 2 Bristol-Myers Squibb, Sanofi, Bluebird,  
 3 Vertex Pharmaceuticals. That's a range of  
 4 them.  
 5 A lot of this information that  
 6 you're actually requesting is publicly  
 7 available online. Because I'm a physician,  
 8 there's something called the CMS Open  
 9 Payments Database, Sunshine Laws, and you can  
 10 see a lot of these things on there as well.  
 11 Q. Is there any other companies  
 12 that you can think of who have paid for your  
 13 work?  
 14 MS. MCENROE: Objection to  
 15 form.  
 16 A. Can you clarify? What do you  
 17 mean, paid for my work?  
 18 BY MR. PIFKO:  
 19 Q. Well, what I'm clarifying is  
 20 I'm guessing you -- do you get a check from  
 21 Precision Health Economics?  
 22 A. I do receive checks from  
 23 Precision Health Economics as a consultant.  
 24 Q. Okay. When these companies are

Page 39

1 hiring you, do they pay you directly?  
 2 A. Sometimes they pay me directly.  
 3 Other times it would be through Precision  
 4 Health Economics. And oftentimes the  
 5 consulting work that I do is not company --  
 6 is not company-specific.  
 7 So, for instance, I might work  
 8 with PHE to try and brainstorm research  
 9 ideas, and they may then talk to companies  
 10 about them, but I would never receive a  
 11 payment from them, from the company itself.  
 12 Q. Okay. All I'm trying to ask is  
 13 however the money comes, whether it's  
 14 directly to you or through Precision Health  
 15 Economics, you just listed a bunch of  
 16 companies, are there any other companies you  
 17 can think of who funded your work?  
 18 MS. MCENROE: Objection to  
 19 form.  
 20 A. There may be other companies,  
 21 not that I can think of. But I would refer  
 22 you to a publicly available database where  
 23 you could sort out that information. But  
 24 those are the companies that come to mind

Page 40

1 right now.  
 2 BY MR. PIFKO:  
 3 Q. Okay. So sitting here today,  
 4 you're not able to remember any other  
 5 companies? That's what I'm asking you.  
 6 MS. MCENROE: Objection to  
 7 form.  
 8 A. Let me spend some more time  
 9 thinking if there's any other companies.  
 10 Years ago I did -- maybe five  
 11 or six years ago I did work for a company  
 12 called Hill-Rom. I've done work probably  
 13 five or six years ago with a company called  
 14 TESARO, T-E-S-A-R-O. And there may be other  
 15 companies beyond that.  
 16 BY MR. PIFKO:  
 17 Q. Okay. But you can't think of  
 18 any other ones?  
 19 MS. MCENROE: Objection to  
 20 form.  
 21 A. No. I gave you a list of about  
 22 ten, I think. That's about as much as I keep  
 23 in my mind at once.  
 24 BY MR. PIFKO:

Page 41

1 Q. Okay. Have you worked for any  
 2 other companies like Precision Health  
 3 Economics?  
 4 MS. MCENROE: Objection. Form.  
 5 A. No. Precision Health Economics  
 6 is the only company that I've done consulting  
 7 work with, what I call health economics  
 8 outcomes research consulting.  
 9 BY MR. PIFKO:  
 10 Q. Okay. On this matter, are you  
 11 retained through Analysis Group?  
 12 A. Yes, that's correct.  
 13 Q. Okay. So Analysis Group writes  
 14 you the check?  
 15 A. That's correct.  
 16 Q. Have you done any work through  
 17 any other companies besides Analysis Group  
 18 and Precision Health Economics?  
 19 MS. MCENROE: Objection to  
 20 form.  
 21 A. No, not besides those.  
 22 As you alluded to earlier, you  
 23 asked earlier have I received any payments  
 24 directly from companies. I have received

Page 42

1 payments directly from some of those  
2 companies that I described.  
3 But in terms of either  
4 economics consulting work, which is under  
5 Precision Health Economics, or litigation  
6 consulting work, which is what I've been  
7 doing with Analysis Group, no other companies  
8 besides those.  
9 BY MR. PIFKO:  
10 Q. Your litigation work, has that  
11 all been through the Analysis Group?  
12 A. Yes, that has been.  
13 Q. So as we discussed at the  
14 beginning, you're doing some consulting for  
15 Rite Aid in the opioid litigation. Setting  
16 that aside, have you done any non-testifying  
17 work with Analysis Group --  
18 MS. MCENROE: Objection.  
19 BY MR. PIFKO:  
20 Q. -- besides the opioid cases?  
21 A. No. The only work I've done  
22 with Analysis Group relates to litigation and  
23 expert witness testimony.  
24 Q. Okay. So the only work that

Page 43

1 you've done for Analysis Group is the three  
2 testifying matters that you listed in your  
3 report and the one we're sitting here today  
4 in, plus some consulting work for Rite Aid in  
5 connection with the opioid litigation, is  
6 that correct?  
7 MS. MCENROE: Objection.  
8 A. In addition to ongoing matters  
9 that I have not -- I have not provided  
10 testimony or filed a report in.  
11 BY MR. PIFKO:  
12 Q. Okay. So there are some other  
13 matters where you have been retained to  
14 potentially be a testifying expert but you  
15 haven't been designated?  
16 MS. MCENROE: Objection to  
17 form.  
18 A. What do you mean by  
19 "designated"?  
20 BY MR. PIFKO:  
21 Q. Well, formally, when we get  
22 your report, or sometimes someone submits a  
23 pleading in the case saying here's my expert,  
24 then it's known to everybody in the case that

Page 44

1 you're the expert.  
2 A. I see.  
3 No. So I can't comment on the  
4 legal term "designated." What I can say is  
5 that I'm engaged in other litigation matters  
6 that I have been retained as an expert in but  
7 I have not filed a report in yet.  
8 Q. Okay. How many matters is  
9 that?  
10 A. Say five or six.  
11 Q. When did you start work on  
12 those?  
13 A. Some of the work would have  
14 started in 2018. Others I've been retained  
15 on in the last month, but I haven't actually  
16 done any work for, I've just been retained.  
17 So when I say five or six, I  
18 mean cases I've been retained for, may not  
19 have billed any hours to that -- to those  
20 cases.  
21 Q. That's what I was going to get  
22 at.  
23 So of these five or six, how  
24 many have you done more than just someone

Page 45

1 called you up and said, "hey, do you want to  
2 work on this?" "Okay."  
3 A. I'd say three, three, four.  
4 About half to two-thirds of them I've done  
5 work, and the other, let's say, quarter I  
6 have not done any work yet.  
7 Q. So of those ones that you have  
8 done some work, that started in 2018?  
9 A. I think that started either  
10 late 2017 or early 2018.  
11 Q. Are those all --  
12 A. Or just to clarify, my work  
13 with Analysis Group started late 2017 or  
14 early 2018. The matters that I've  
15 been retained in that I haven't filed reports  
16 in, I think that the onset of those matters  
17 is probably late 2018, because, as I  
18 mentioned, some of them I have not been --  
19 done any work in yet. I've just been  
20 retained.  
21 Q. Do you understand the clients  
22 who hired you to be confidential?  
23 A. Can you clarify?  
24 Q. Those clients where you haven't

Page 46

1 filed a report, do you understand -- are you  
2 allowed to tell me who they are?  
3 MS. MCENROE: Objection to  
4 form.  
5 A. I'm not aware if I'm allowed to  
6 tell you or not. I would suspect that I'm  
7 not allowed to tell you.  
8 BY MR. PIFKO:  
9 Q. Okay. During the break,  
10 whenever we take a break, I'd like you to  
11 look into that and see if you're able to tell  
12 me. Okay?  
13 MS. MCENROE: And we'll talk  
14 about it, and then we'll let you know,  
15 Mark.  
16 BY MR. PIFKO:  
17 Q. Let's talk about what we can --  
18 whatever we can talk about about those.  
19 Are those all in the  
20 pharmaceutical area?  
21 A. They are mostly -- they're all  
22 in the healthcare area.  
23 Q. When I say "all of them," I'm  
24 talking about all five or six.

Page 47

1 A. That's what I'm responding to.  
2 Yes.  
3 Q. Okay. So they're all in the  
4 health care field?  
5 A. Yes.  
6 Q. Your clients in those, do you  
7 know what field of classification they're in?  
8 MS. MCENROE: Objection to  
9 form.  
10 A. Sure. Yes. So in one or  
11 two -- maybe one or two cases, they're  
12 biologic drugs to treat cancer. One of the  
13 cases is a blood thinner. One of the cases  
14 is a diagnostic test. And the other case, I  
15 think, involves a few drugs, an antibiotic,  
16 possibly a proton pump inhibitor, it's like a  
17 reflux medication. None of them have to do  
18 with opioids.  
19 BY MR. PIFKO:  
20 Q. All these matters, you've been  
21 retained by a company who is in the business  
22 of producing the drug or the product?  
23 MS. MCENROE: Objection to  
24 form.

Page 48

1 A. Yes.  
2 BY MR. PIFKO:  
3 [REDACTED]  
4 [REDACTED]  
5 [REDACTED]  
6 [REDACTED]  
7 [REDACTED]  
8 [REDACTED]  
9 [REDACTED]  
10 [REDACTED]  
11 [REDACTED]  
12 [REDACTED]  
13 [REDACTED]  
14 [REDACTED]  
15 [REDACTED]  
16 [REDACTED]  
17 [REDACTED]  
18 [REDACTED]  
19 [REDACTED]  
20 [REDACTED]  
21 [REDACTED]  
22 [REDACTED]  
23 [REDACTED]  
24 [REDACTED]

Page 49

1 BY MR. PIFKO:  
2 Q. Have you been paid at any time  
3 to be a speaker at a conference or a  
4 presentation of any kind?  
5 A. Can you clarify what you mean  
6 by that?  
7 Q. Well, has any -- okay. Just  
8 have you ever been paid to give a lecture?  
9 A. I have been paid to give  
10 lectures, but not been paid by pharmaceutical  
11 companies to deliver lectures about their  
12 products.  
13 For instance, I gave a named  
14 lecture at the American College of Radiology  
15 called the Morton Lecture last year. It's a  
16 lecture that's given once a year by the ACR,  
17 and they ask a, you know, a speaker to come  
18 and give a talk. It's a prestigious thing  
19 with 800 to 1,000 people there. So I would  
20 have been paid to give that commentary.  
21 I give grand rounds  
22 presentations, so I gave a grand rounds  
23 presentation at University of Texas  
24 Southwestern. And it's common for an



Page 50

1 institution to pay a professor to come to  
2 give a talk, and it's called an honorarium,  
3 and also to pay travel.  
4 That's different than -- I have  
5 not been paid to talk about the benefits of  
6 one drug versus another by a drug company or  
7 anything like that.  
8 Q. Okay. But I think the thing --  
9 the benefits of a drug or another, that's  
10 like a speaker program. Have you ever heard  
11 that term before?  
12 A. Yes, I've heard that term.  
13 Q. So you've never served as a --  
14 in a speaker program for any company?  
15 A. Correct. I've never served,  
16 and I've never actually been to a speaker  
17 program event.  
18 Q. Okay. And then you -- when you  
19 were just talking about your academic income,  
20 you mentioned giving lectures and things,  
21 maybe not always at Harvard, maybe at other  
22 universities for income. And you said  
23 something, I think, that that academic  
24 institution pays you for that. Was I -- did

Page 51

1 I hear you correctly?  
2 A. Yes, you did.  
3 Q. Okay. So you were just talking  
4 about giving some of the grand rounds and  
5 some other types of lectures. Was that in  
6 the context of where you're getting an  
7 academic payment?  
8 A. That's an academic, yeah.  
9 That's pretty standard across all of  
10 academics actually. You know, if an English  
11 professor goes to give -- he's at Harvard,  
12 goes to give a talk at Brown, they may pay  
13 him a \$500 honorarium to come and give a  
14 talk.  
15 Q. Okay.  
16 A. That's exactly what I'm  
17 referring to.  
18 Q. So then, aside from like a  
19 speaker program or these academic programs,  
20 have you ever been paid to give, like, a  
21 lecture or something anywhere at a conference  
22 or like at a -- attend a corporate office and  
23 give a speech or anything like that?  
24 MS. MCENROE: Objection to

Page 52

1 form.  
2 A. Not that I know of. I mean, I  
3 would go meet with -- as -- we talked about  
4 me doing consulting work, so I've gone to  
5 companies and talked about research, but not  
6 in a -- not to, like, talk about a specific  
7 drug or anything like that.  
8 BY MR. PIFKO:  
9 Q. Well, or anything, you know,  
10 like presidents get hired to come speak at  
11 corporations.  
12 A. Oh, I see. No, I have not been  
13 hired in the way that Barrack Obama has been  
14 hired, no.  
15 Q. Okay.  
16 A. Yeah.  
17 Q. Well, some experts have been  
18 paid to come visit some corporation and give  
19 a talk about something.  
20 A. Yeah. No, no. If you're  
21 referring to experts, people getting paid  
22 \$20,000 to go give a talk at the retreat of a  
23 major company, no, I've not done that before.  
24 Q. Okay. How about -- so you

Page 53

1 all -- you do research as part of your work,  
2 correct?  
3 A. That's almost all what I do,  
4 yeah.  
5 Q. Okay.  
6 A. I'm a researcher.  
7 Q. So when you're doing -- and  
8 you've written, I believe your CV says  
9 somewhere around the neighborhood of --  
10 you've had around 150 published articles or  
11 so. Does that sound right?  
12 A. That's correct, about 150  
13 scientific articles, so peer-reviewed  
14 articles. Probably another 40 to 50 articles  
15 that I've authored in the lay press.  
16 Q. So the distinguishment you just  
17 made there is the 150 are, like, in academic  
18 or medical-type journals?  
19 A. That's correct, or economics  
20 journals.  
21 Q. Okay.  
22 A. But academic journals is a good  
23 descriptor.  
24 Q. Okay. And then the lay press

Page 54

1 is like if you write an opinion piece in a  
2 newspaper, magazine, or something like that?  
3 A. Yeah, it could be -- so a lay  
4 press is really meaning not peer-reviewed.  
5 For instance, if I wrote a  
6 piece in the Harvard Business Review, that  
7 wouldn't be peer-reviewed by other scholars.  
8 And so that's a -- I distinguish that kind of  
9 piece from an article of mine in the New  
10 England Journal of Medicine. And I've  
11 published in Harvard Business Review,  
12 Washington Post, New York Times, Wall Street  
13 Journal, places like that.  
14 Q. Do you receive an income from  
15 writing those lay press articles?  
16 A. No, I don't receive any income  
17 from that. They sometimes -- to be clear,  
18 the New York Times, for example, will -- if  
19 you write an op ed in the New York Times, I  
20 think that they will pay you a couple hundred  
21 bucks if you request it. I usually don't  
22 because it's a lot of effort to go through  
23 their accounts processing system or whatever  
24 it's called, so I usually don't do that. But

Page 55

1 that offer is there, and it varies across  
2 outlets. HBR, Harvard Business Review, for  
3 example, doesn't pay. I know that.  
4 Q. Okay. So things like the New  
5 York Times thing, it's just not worth the  
6 complication of what you have to jump through  
7 to get the money?  
8 MS. MCENROE: Objection to  
9 form.  
10 A. Well, I don't know what -- not  
11 worth it. \$200 is \$200. That's a -- it's --  
12 I've tried to do the thing before, and it  
13 doesn't work out. And so aside from many  
14 other things I've got to do, I end up not  
15 getting paid.  
16 BY MR. PIFKO:  
17 Q. Give me some leeway. I don't  
18 know if I use all the right terminology here.  
19 But if I want to ask, like, so you have --  
20 not every peer-reviewed article is about  
21 original research. I mean, maybe you do like  
22 a -- you know, maybe you -- what -- I guess  
23 what I'm -- I want to talk about data-driven  
24 research where you're collecting the data

Page 56

1 versus -- what's the term where you review a  
2 bunch of articles and then write a summary  
3 about that?  
4 MS. MCENROE: Objection to  
5 form.  
6 BY MR. PIFKO:  
7 Q. So do you do research where you  
8 are in a, you know, clinical trial or  
9 something where you're collecting original  
10 data?  
11 MS. MCENROE: Objection to  
12 form.  
13 A. I do data-driven research, not  
14 in a clinical trial setting. I analyze data.  
15 It's called observational data. So I use  
16 Medicare claims data, insurance claims data,  
17 other publicly available databases, and I  
18 answer questions based on that data. I've  
19 never conducted a randomized controlled  
20 trial.  
21 BY MR. PIFKO:  
22 Q. When you do the research  
23 projects, are they funded by outside funding?  
24 MS. MCENROE: Objection. Form.

Page 57

1 A. The research that I do, some of  
2 it is funded by NIH grants. Others of it is  
3 unfunded research, I just do it because, as  
4 part of my faculty appointment at Harvard,  
5 I'm -- you know, I'm paid to teach and do  
6 research, and so I just do research through  
7 my salary basically.  
8 BY MR. PIFKO:  
9 Q. Okay. And what I'm trying to  
10 get at is any of those research projects, are  
11 aspects of the research -- maybe you  
12 personally don't get a check, but is parts of  
13 the research funded by any private  
14 corporations outside of the university?  
15 A. I see.  
16 MS. MCENROE: Objection to  
17 form.  
18 A. So some of the -- some of the  
19 papers on my CV and -- some of the papers on  
20 my CV reflect projects where it would have  
21 been a project that I did with Precision  
22 Health Economics, and that would have been  
23 often, but maybe not always, funded by an  
24 industry sponsor. And they are, you know,

Page 58

1 very clearly -- often there's even industry  
2 authors that will -- it's a collaborative  
3 effort, we work with industry authors, we  
4 write a paper and disclose the funding as  
5 well. And some of the work in my CV reflects  
6 that kind of research.  
7 BY MR. PIFKO:  
8 Q. And the companies that have  
9 made those type of payments, we talked about  
10 those already?  
11 A. That's correct.  
12 Q. There's no other companies that  
13 have provided that kind of funding that you  
14 can think of sitting here today?  
15 MS. MCENROE: Objection to  
16 form.  
17 A. There may be other companies,  
18 but I think that that's probably a pretty  
19 exhaustive list. I would defer to you to  
20 look through the papers and see if there's  
21 any other sources, but I think that that's  
22 pretty accurate.  
23 BY MR. PIFKO:  
24 Q. Okay. Well, I'm just asking,

Page 59

1 we're in the deposition setting, that's all  
2 you can remember today?  
3 A. That's correct.  
4 Q. Do you intend to continue doing  
5 litigation consulting?  
6 MS. MCENROE: Objection to  
7 form.  
8 A. I plan to continue to do it,  
9 but it depends on what other opportunities  
10 come my way in terms of research and family  
11 obligations and things like that.  
12 BY MR. PIFKO:  
13 Q. Let's talk about how you came  
14 to be retained in this matter, okay?  
15 A. Sure.  
16 Q. When did you first -- well,  
17 actually, scratch that.  
18 I want to ask you, how did you  
19 first come to be involved with Analysis  
20 Group?  
21 A. I started working with Analysis  
22 Group, I believe, sometime in 2018. I may  
23 have been approached by them either late --  
24 very late 2017 or early 2018, primarily

Page 60

1 because of my expertise. I have a PhD in  
2 economics, a medical degree, I see patients,  
3 I write about economic issues in health care,  
4 and so my background lends itself very well  
5 to this kind of work.  
6 Q. So someone from Analysis Group  
7 made a cold call to you and asked if you  
8 wanted to be involved with them?  
9 A. Someone in Analysis Group  
10 reached out to me through a mutual  
11 acquaintance.  
12 Q. Okay. Do you remember their  
13 name?  
14 A. Yes. Stephen Fink.  
15 Q. He works at Analysis Group?  
16 A. Yes.  
17 Q. Then I want to ask you, sorry,  
18 Precision Health Economics, do you have an  
19 official position there?  
20 A. What do you mean by "official  
21 position"?  
22 Q. Do you have a title being  
23 affiliated with --  
24 A. I think if you look at their

Page 61

1 website, they may say something like research  
2 affiliate or something like that. You know,  
3 it's probably pretty standard, just like I  
4 could be a fellow at some institution. I'm  
5 not like a VP of something or senior  
6 director. If that's what you mean by  
7 "title," then no. But there would be my name  
8 on a website, I'm assuming, plus something  
9 after it.  
10 Q. Okay. Right.  
11 So what I was trying to get at  
12 is, do you view yourself as having any sort  
13 of formal employment, ongoing employment with  
14 Precision Health Economics?  
15 MS. MCENROE: Objection to  
16 form.  
17 A. I view myself as being a  
18 consultant to them. So I can stop consulting  
19 with them today or tomorrow without  
20 any problem. I don't get any health benefits  
21 or anything like that from them, so they're  
22 not an employer at all the same way that  
23 Harvard or Mass General is an employer of  
24 mine.

Page 62

1 Q. Okay. So Stephen Fink reached  
2 out to you from Analysis Group?  
3 A. That's correct.  
4 Q. And he knew someone else that  
5 you knew?  
6 A. That's correct.  
7 Q. Who was that person there?  
8 A. That's his wife. I knew -- his  
9 wife is a physician at Mass General.  
10 Q. What's her name?  
11 A. Sarah Turbett, T-U-R-B-E-T-T.  
12 Q. So Stephen Fink reached out to  
13 you and said, hey, would you like to start  
14 doing some litigation consulting through  
15 Analysis Group?  
16 MS. MCENROE: Objection to  
17 form.  
18 A. Stephen Fink reached out and  
19 said, are you -- have you ever done any  
20 litigation consulting work before, and I said  
21 no, I had not done litigation work before,  
22 I'd done other consulting. And I was curious  
23 about the types of work that happens in this  
24 space, which is obviously old news to you but

Page 63

1 was news to me at that time, and I thought it  
2 was an area where the set of skills that I've  
3 developed and the expertise could actually be  
4 very helpful.  
5 BY MR. PIFKO:  
6 Q. And so did you meet with him in  
7 person, or just talk on the phone at that  
8 time?  
9 A. I think we probably met in  
10 person.  
11 Q. Then did he ask you to start  
12 work on a specific project right away at that  
13 time?  
14 A. No. It probably would have  
15 been months, maybe six, seven months before I  
16 actually did any work.  
17 Q. So you left that meeting  
18 basically telling him, yeah, I'm interested  
19 in doing this kind of work, if you have  
20 something that -- where someone needs my  
21 expertise, I'd be happy to be involved?  
22 MS. MCENROE: Objection to  
23 form.  
24 A. Yeah, I left the meeting saying

Page 64

1 this is an interesting line of work, the  
2 questions that are being asked are really  
3 important.  
4 And I spend a lot of my time,  
5 for lack of better words, in data, in theory.  
6 Being able to be part of litigation allows me  
7 to take the stuff that I think about in a  
8 room where I'm working with a computer and  
9 writing papers and writing policy pieces to  
10 be able to translate into real life.  
11 And so when I left that  
12 meeting, I thought this is quite interesting.  
13 It's -- you know, I've never been involved in  
14 this kind of work before. I can see how the  
15 way I think about the world, the questions  
16 that I've asked, the answers that I've found  
17 in my research could be impactful in shaping  
18 how actual things happen in the real world.  
19 BY MR. PIFKO:  
20 Q. And then six months or so later  
21 he called you with a specific assignment?  
22 A. I think the first -- the first  
23 assignment was what you see there, which was  
24 the antitrust matter. And my guess is that

Page 65

1 at the time Analysis Group was working with  
2 another law firm on this matter, and they  
3 were at the point of the work where they were  
4 trying to identify experts.  
5 And I had told Steve -- I was  
6 like, Steve, I'm interested in this kind of  
7 work, things that are health care-related,  
8 things that rely on the economics of  
9 innovation, things that rely on issues of  
10 defining health care markets, things that  
11 rely on issues of physician behavior and  
12 prescribing and opioids. I've done a lot of  
13 work on opioids. This had not started at  
14 that point yet. Things of that nature I'd be  
15 interested in.  
16 And so I suspect, although I  
17 don't know the mechanics of what happened on  
18 their end, is that they put my name forth as  
19 an expert -- potential expert to the law  
20 firm, and sometime after that I was retained  
21 in that matter.  
22 (Whereupon, Jena Exhibit Number  
23 1 was marked for identification.)  
24



<p style="text-align: right;">Page 66</p> <p>1 BY MR. PIFKO:  2 Q. I'm handing you what's marked  3 as Exhibit 1.  4 A. Thank you.  5 Q. Which is --  6 MS. MCENROE: Thank you.  7 BY MR. PIFKO:  8 Q. -- Appendix B to the expert  9 report you provided in this case, which is  10 the list of testimony. Take a minute to look  11 at that, and let me know when you're done.  12 A. All set.  13 Q. So is this a true and correct  14 list of matters where you provided testimony?  15 A. That's correct.  16 Q. So the antitrust litigation,  17 that was the first matter that you worked on?  18 A. Yes.  19 Q. Do you know who the law firm  20 was for that?  21 A. I think Kirkland &amp; Ellis.  22 Q. Do you remember the names of  23 the lawyers that you worked with?  24 A. No. I remember the names of</p>	<p style="text-align: right;">Page 68</p> <p>1 side, do you remember the name of the law  2 firm on the other side, or any of the  3 lawyers' names?  4 A. No.  5 Q. All right. Let's go to the  6 second matter, the Ranbaxy matter. Do you  7 remember the name of the law firm?  8 A. That was -- those two are the  9 same law firms.  10 Q. Okay. That was Kirkland &amp;  11 Ellis as well?  12 A. Yes.  13 Q. Do you remember any of the  14 names on that one?  15 A. And it would have been the same  16 counsel on there.  17 Q. How about on that arbitration  18 matter, the Ranbaxy matter, do you remember  19 the name of the lawyers on the other side?  20 A. No, nor the firm.  21 Q. Okay. And then the Amphastar  22 matter, do you know the name of the law firm  23 that hired you?  24 A. No, I do not know the name of</p>
<p style="text-align: right;">Page 67</p> <p>1 the lawyers in this room, but I couldn't tell  2 you the names of all the different -- no  3 disrespect to counsel -- I don't remember the  4 name of all the lawyers.  5 Q. Okay. You don't remember any  6 of their names?  7 A. Let me just look at this list  8 here.  9 Q. Just on -- but just on that  10 matter.  11 A. For this one, if I give you  12 first names, is that okay?  13 Q. Yeah.  14 A. Devora.  15 Q. Whatever you remember.  16 A. Devora, D-E-V-O-R-A. Oh, yeah,  17 no --  18 Q. Okay.  19 A. -- that's the extent of my  20 recollection.  21 Q. Do you know what office, in  22 what city?  23 A. New York, that I know.  24 Q. How about lawyers on the other</p>	<p style="text-align: right;">Page 69</p> <p>1 the law firm.  2 Q. How about any of the lawyers?  3 A. No.  4 Q. How about the law firm on the  5 other side?  6 A. Definitely not that.  7 Q. Okay. And so then looking at  8 these, in the antitrust matter, you only  9 provided a deposition, you didn't testify in  10 trial?  11 A. That's correct.  12 Q. Do you know the outcome of that  13 case?  14 A. I believe it's still ongoing.  15 Q. Do you know if any motions were  16 filed to exclude you or --  17 A. No motions have been filed in  18 any of these matters to exclude me.  19 Q. Okay. The Ranbaxy matter, do  20 you know the outcome of that matter?  21 A. That was an arbitration. I  22 don't know the -- so I know that there was an  23 outcome. I just don't know what the outcome  24 was.</p>



Page 70

1 Q. Okay. You don't know if there  
 2 was a finding in favor or against your  
 3 client?

4 A. I think there was a finding in  
 5 favor of my client, but I'm -- again, I don't  
 6 know exact details of what that would look  
 7 like. But I do know that there was an  
 8 outcome because there was an arbitration,  
 9 there was some period of time after the  
 10 arbitration they were supposed to come up  
 11 with some ruling or some judgment.

12 Q. Okay. And then the Amphastar  
 13 matter, do you know the outcome of that  
 14 matter?

15 A. This matter is still ongoing.

16 Q. Do you know if there were any  
 17 motions to exclude you --

18 A. No.

19 Q. -- or challenge your testimony?

20 A. No motions of that sort have  
 21 ever been filed against me.

22 Q. And then so -- and the  
 23 Amphastar matter, you testified in  
 24 deposition, but that was it?

Page 71

1 A. The trial has not occurred yet.

2 Q. And then in the Ranbaxy matter,  
 3 you gave a deposition, and then you also  
 4 testified at the arbitration hearing?

5 A. I think that those are one and  
 6 the same. But again, I -- I believe that  
 7 they're one and the same. I think what I did  
 8 is I filed a report and then gave a testimony  
 9 and was questioned in an arbitration. I  
 10 don't think I did something else formal  
 11 before that.

12 Q. Okay.

13 MS. MCENROE: Mark, when we  
 14 reach a good chance to take a quick  
 15 break, I would appreciate it.

16 MR. PIFKO: We can take a  
 17 break.

18 THE VIDEOGRAPHER: The time is  
 19 12:07 p.m., and we're off the record.  
 20 (Whereupon, a recess was  
 21 taken.)

22 THE VIDEOGRAPHER: The time is  
 23 12:22 p.m., and we're on the record.  
 24

Page 72

1 BY MR. PIFKO:

2 Q. So off the record we were just  
 3 discussing the litigation consulting where  
 4 you have not filed a report. And I  
 5 understand that you're -- you do not  
 6 understand yourself to be able to -- to  
 7 identify the clients, is that correct?

8 A. That's correct.

9 MS. MCENROE: Object to form.

10 A. I apologize.

11 That's correct.

12 MS. MCENROE: And I just want  
 13 to make sure it's clear, it's not that  
 14 he's not able to identify who they  
 15 are, it's that their identities are  
 16 confidential at this point.

17 BY MR. PIFKO:

18 Q. Let's talk about how you came  
 19 to be retained in this particular matter,  
 20 okay?

21 A. Sure.

22 Q. So when were you first  
 23 contacted about providing work in the opioid  
 24 litigation?

Page 73

1 A. I think sometime in 2018.

2 Q. Who first contacted you?

3 A. I believe I was first contacted  
 4 by Analysis Group.

5 Q. Who at Analysis Group?

6 A. I'm not sure who it would be,  
 7 but quite possibly Stephen Fink.

8 Q. What did he tell you at that  
 9 time?

10 MS. MCENROE: Objection to  
 11 form.

12 A. At that time probably just  
 13 described the litigation. I was aware that  
 14 litigation was ongoing, and he described to  
 15 me a potential client who may be interested  
 16 in hearing, you know, my thoughts on these  
 17 issues. That would have been the nature of  
 18 the discussion.

19 BY MR. PIFKO:

20 Q. You were aware that the opioid  
 21 litigation was going on?

22 A. I think I was vaguely aware. I  
 23 may -- and I don't know the timing of it, but  
 24 I think I was vaguely aware that something

Page 74

1 was going on.  
2 Q. What did you understand about  
3 the opioid litigation around this time --  
4 MS. MCENROE: Objection to  
5 form.  
6 BY MR. PIFKO:  
7 Q. -- when you were first being  
8 asked to work on this matter?  
9 A. At a very cursory level, that  
10 organizations were being sued by local  
11 jurisdictions.  
12 Q. Where was the basis of that  
13 understanding?  
14 A. Just news media.  
15 Q. Had you developed a particular  
16 interest in the litigation at that time  
17 independent of being retained to work on it?  
18 MS. MCENROE: Objection to  
19 form.  
20 A. No particular interest in the  
21 litigation. I work -- as you can see from my  
22 CV, I work a lot on opioids and have done so  
23 for years. So when Analysis Group approached  
24 me about this potential matter, you know, I

Page 75

1 was a good fit for it because I've thought a  
2 lot about these issues, I know about the  
3 medicine, the economics, the health policy  
4 issues that are involved, and I've written  
5 about these issues as well.  
6 BY MR. PIFKO:  
7 Q. And so Stephen Fink or somebody  
8 from Analysis Group spoke to you, and you  
9 said you wanted to be involved?  
10 A. When they spoke to me, I said  
11 this is an interesting case, I'd like to  
12 learn more.  
13 Q. Okay. And then who did you  
14 talk to?  
15 A. At some point I would have  
16 spoken to counsel from Morgan Lewis. And I  
17 don't recall who was on the initial call.  
18 Could be these individuals here. But I had a  
19 call with Morgan Lewis. Analysis Group was  
20 also on the phone call, and I -- then I heard  
21 what some of the issues were.  
22 Q. We have your invoices, which  
23 I'll go over with you in a little bit. But  
24 would you have started to write down your

Page 76

1 time beginning with that first call?  
2 A. I think I probably would have  
3 started writing down my time after I was  
4 retained. So usually if I have a call with  
5 someone, I don't write down the time because  
6 I haven't been retained and there's no  
7 expectation. But after I would have been  
8 retained formally, then I would have started  
9 writing down time.  
10 Q. Okay. So you -- do you have a  
11 sense of when this first call might have  
12 been?  
13 A. I don't. Sometime in 2018.  
14 But the invoices will actually be very clear  
15 on that, I think.  
16 Q. Well, that's what I was getting  
17 at.  
18 If we look at the invoices --  
19 so it's your testimony that that invoice  
20 likely would not reflect this first call  
21 because you hadn't formally been retained  
22 yet?  
23 A. The initial call? I suspect  
24 not, but, again, I'd have to look at the

Page 77

1 invoice and see. I mean, I can just tell you  
2 as a general matter on these matters, for  
3 lack of better words, I usually don't charge  
4 a bill for -- you know, bill for that first  
5 call because I haven't been retained yet.  
6 But it kind of depends on the context.  
7 And I've also looked at  
8 guidance from Analysis Group to say, well,  
9 should I bill for this call or not. And that  
10 -- so I don't know exactly in this matter  
11 what I would have done, but that's my general  
12 policy towards these things.  
13 Q. Okay. And then at some point  
14 after that call you became formally retained?  
15 A. That's correct.  
16 Q. What did you understand the  
17 scope of your assignment to be?  
18 A. When I was initially retained,  
19 I was retained not with a specific assignment  
20 at that time. I think my assignment became  
21 more clear -- the scope of the assignment  
22 became more clear later in either late 2018  
23 or probably closer to early 2019, which is  
24 when I really went in earnest in developing

Page 78

1 my report.  
2 Q. When you did come to an  
3 understanding about what the scope of work  
4 was, what was your understanding of what the  
5 scope of work was?  
6 MS. MCENROE: Objection to  
7 form.  
8 A. So I can -- I could point you  
9 to the specific part of my assignment, but  
10 there's basically three broad categories.  
11 First was to assess a  
12 particular plaintiff's expert, Dr. McCann, in  
13 the nature of a suspicious order flagging  
14 methodology and just to assess it from an  
15 academic perspective; is this a credible  
16 methodology or not? Would it pass muster  
17 based on reliance on scientific evidence and  
18 methods? And my short answer to that is no.  
19 The second was to assess the  
20 quality of Rite Aid's anti-diversion  
21 practices.  
22 And the third was to assess the  
23 harm, if any, that would have arisen from  
24 Rite Aid's practices as it relates to

Page 79

1 diversion from harm.  
2 Those are the three kind of  
3 cornerstones of my assignment.  
4 Q. When you first became retained,  
5 if you didn't have a clear scope of work,  
6 what did you understand yourself -- what did  
7 you understand you were supposed to be doing?  
8 MS. MCENROE: Objection to  
9 form.  
10 A. When I was first -- from the  
11 period when I was first retained until when I  
12 started working in earnest on the report,  
13 there's a series of consulting work that was  
14 done by Rite Aid, which I was pretty  
15 peripherally involved. There may be some  
16 topics here that I would chime in on, but I  
17 really wasn't fully engaged until the last  
18 several months where I started working on my  
19 report.  
20 MS. MCENROE: Mark, I think  
21 they should be chronologically  
22 ordered.  
23 MR. PIFKO: Okay. We'll find  
24 out.

Page 80

1 BY MR. PIFKO:  
2 Q. I'm going to be handing you  
3 some materials that were provided to me  
4 yesterday by counsel for Rite Aid.  
5 (Whereupon, Jena Exhibit Number  
6 2 was marked for identification.)  
7 BY MR. PIFKO:  
8 Q. The first thing I'm handing you  
9 is what's marked as Exhibit 2.  
10 A. Thank you.  
11 THE WITNESS: I have five  
12 copies.  
13 MS. MCENROE: Oh, yeah.  
14 MR. PIFKO: Let's go off the  
15 record so we can collate these.  
16 THE VIDEOGRAPHER: The time is  
17 12:31 p.m. We're off the record.  
18 (Whereupon, a recess was  
19 taken.)  
20 THE VIDEOGRAPHER: The time is  
21 12:36 p.m., and we're on the record.  
22 BY MR. PIFKO:  
23 Q. Okay. You have in front of you  
24 what's marked as Exhibit 2, which are some

Page 81

1 materials that I received yesterday. Take a  
2 minute to review those, and let me know when  
3 you're done.  
4 A. I've reviewed them.  
5 Q. For the record, Exhibit 2 is  
6 six pages. Can you tell me what Exhibit 2  
7 is?  
8 A. So Exhibit 2 appears to be  
9 timesheet that I e-mail to Analysis Group for  
10 my work on --  
11 PHONE PARTICIPANT: Sorry to  
12 interrupt, but we're having trouble,  
13 at least on my end, hearing you guys  
14 over the phone.  
15 THE VIDEOGRAPHER: The time is  
16 12:37 p.m. We're off the record.  
17 (Off the record discussion.)  
18 THE VIDEOGRAPHER: The time is  
19 12:39 p.m., and we're on the record.  
20 BY MR. PIFKO:  
21 Q. Okay. So looking at Exhibit 2,  
22 you said that you e-mail your time to  
23 Analysis Group?  
24 A. That's correct.

Page 82

1 Q. Did you prepare Exhibit 2?  
2 MS. MCENROE: Objection to  
3 form.  
4 A. This is -- these spreadsheets  
5 are what I send them, or I have been sending  
6 them since, it looks like, April of 2018. I  
7 didn't do any additional preparation of these  
8 myself.  
9 BY MR. PIFKO:  
10 Q. Okay. So you -- this is a  
11 form -- the same format that you use? You  
12 put it into like an Excel file and send it to  
13 them?  
14 A. Yeah, it looks like actually  
15 the exact -- exact format.  
16 Q. Okay. So does this reflect all  
17 the work that you performed on the case --  
18 MS. MCENROE: Objection to  
19 form.  
20 BY MR. PIFKO:  
21 Q. -- to date?  
22 A. This reflects the work as of  
23 April 30, 2019. So any work that would have  
24 been done the month of May I have not

Page 83

1 submitted any timesheet on.  
2 Q. Okay. So other than the month  
3 of May, does that reflect all the work that  
4 you've done?  
5 MS. MCENROE: Objection to  
6 form.  
7 A. Yeah, month of May and month of  
8 June, which is a few days.  
9 BY MR. PIFKO:  
10 Q. So these are true and correct  
11 copies of all the work you performed before  
12 May, 2019 on this matter?  
13 MS. MCENROE: Objection to  
14 form.  
15 A. Yes, before -- on or before  
16 April 30, 2019, that's correct.  
17 BY MR. PIFKO:  
18 Q. Looking at the first page of  
19 Exhibit 2, does this refresh your  
20 recollection about when you were retained in  
21 this matter?  
22 A. What I can see here is that on  
23 April 27, 2018, I billed half an hour for a  
24 counsel call. I don't recall whether or not

Page 84

1 that was the initial call per our earlier  
2 conversation, or whether this is a follow-up  
3 call that might have happened sometime later.  
4 I would imagine that the proximity between  
5 this date and when I was retained would have  
6 been pretty close.  
7 Q. So you likely would have been  
8 retained sometime in April, 2018?  
9 A. Yeah, sometime in March or  
10 April, 2018.  
11 Q. And then you said you didn't  
12 really get started on the report until  
13 sometime later. Looking at these time  
14 entries, when would you say you started  
15 working on the report?  
16 MS. MCENROE: Objection to  
17 form.  
18 A. So looking at the time entries,  
19 looks like March of 2019.  
20 BY MR. PIFKO:  
21 Q. So the work that you did prior  
22 to March, 2019 is not related to forming your  
23 opinions that are in your report?  
24 MS. MCENROE: Objection to

Page 85

1 form.  
2 A. The opinions that are in my  
3 report relate to a specific assignment that I  
4 was asked to do. The work that predates that  
5 was consulting work that I was kind of  
6 peripherally involved in. It helped build  
7 awareness of some of the issues.  
8 So, for instance, there's data  
9 sets that I rely on in my report, like the  
10 ARCOS data, that I probably would have seen  
11 prior to March of 2019, which is incredibly  
12 helpful because you can't just analyze a data  
13 set in one week and expect to know what it  
14 entails.  
15 So there's part of the  
16 report -- parts of the billings before March  
17 of 2019 that would have been relevant, but my  
18 report relates to a specific assignment, and  
19 that assignment was not handed down to me  
20 until, you know, sometime probably in March,  
21 I would guess.  
22 BY MR. PIFKO:  
23 Q. Of 2019?  
24 A. Of 2019, yes.



Page 86

1 Q. The last month -- prior to  
2 March, 2019, the last time you worked on the  
3 case was July 20, 2018, is that correct?  
4 MS. MCENROE: Objection to  
5 form.  
6 A. That looks correct.  
7 BY MR. PIFKO:  
8 Q. You didn't do anything on the  
9 case between July 20, 2018 and March 18,  
10 2019, correct?  
11 A. Not --  
12 MS. MCENROE: Objection to  
13 form.  
14 A. Not that I'm aware of.  
15 BY MR. PIFKO:  
16 Q. You finalized your report on  
17 May 10th?  
18 A. That sounds right. I'd have to  
19 look at the report, but that sounds right.  
20 Q. The last entry on Exhibit 2 is  
21 April 30, 2019. Agree?  
22 A. I agree with that.  
23 Q. Okay. Let's talk about the  
24 work that you did after that up until

Page 87

1 finalizing your report, okay?  
2 A. Sure.  
3 Q. Do you know about how many  
4 hours you spent, well, in May working on your  
5 report?  
6 A. So between April 30th to  
7 May 10th, if I had to guess, I would say  
8 probably maybe 20 to 30 hours, if I had to  
9 guess, somewhere in that ballpark. 10 to  
10 30 hours. It's a broad range, I realize, but  
11 that's obviously a busy time.  
12 Q. So just for clarity, I don't  
13 want you to guess in the deposition, and  
14 maybe that's just a term that lawyers use,  
15 but you are allowed to provide an estimate.  
16 But a guess is just a shot in the dark like,  
17 you know --  
18 A. I see.  
19 Q. -- I don't have -- if I just  
20 would have guessed how much money you have in  
21 your wallet, I have no idea, versus  
22 estimating how much money I might have in my  
23 wallet, I might not know the exact number but  
24 I probably could have a good estimate.

Page 88

1 Do you understand the  
2 difference?  
3 A. Understood.  
4 Q. Okay. So when you say that you  
5 worked 20 to 30 hours in May, that's an  
6 estimate?  
7 A. I would estimate that between  
8 the dates of April 30th to the filing of the  
9 report on May 10th, my estimate is that I  
10 worked 20 to 30 hours.  
11 Q. Okay. And you have recorded  
12 your time just like you did on Exhibit 2, but  
13 you just haven't sent a bill for that yet?  
14 A. That is correct.  
15 Q. Have you sent that to Analysis  
16 Group yet?  
17 A. No.  
18 Q. What's the protocol that you  
19 use to send your time to Analysis Group?  
20 MS. MCENROE: Objection to  
21 form.  
22 A. Sometimes I will e-mail a  
23 document at the end of the month or in the  
24 first week of the following month. Other

Page 89

1 times, if there's a clear goal, benchmark or  
2 goalpost, I'll wait until that.  
3 So, for instance, if there's a  
4 deposition on June 10th, I probably would not  
5 have -- I probably would have waited until  
6 after the deposition because I would not  
7 expect any other subsequent work to be done  
8 on that project. So that just saves the  
9 hassle of having to send two different  
10 invoices.  
11 BY MR. PIFKO:  
12 Q. Okay. So what I'm hearing you  
13 say basically is -- today is June 5th, is  
14 that correct?  
15 A. That's correct.  
16 MS. MCENROE: Objection.  
17 It's June 6th.  
18 BY MR. PIFKO:  
19 Q. Okay. June 6th. All right.  
20 So given that we're only a few  
21 days into June, you're going to submit your  
22 May time along with the work up until now not  
23 long after, and then just have one invoice?  
24 A. So --



Page 90

1 MS. MCENROE: Objection to  
2 form.  
3 A. So I'll submit sometime after  
4 today because I haven't submitted it yet, and  
5 it depends on what else I have to do.  
6 And sometimes Analysis Group  
7 may reach out to me and say, oh, have you  
8 sent us your, you know, billings for this  
9 month, and I would say, oh, I completely  
10 forgot because I've got other things I've got  
11 to take care of.  
12 BY MR. PIFKO:  
13 Q. Do you have a document where  
14 you've been putting in your May time?  
15 A. Not yet, in part because I kind  
16 of go back retrospectively and try to figure  
17 out what I would have been doing on these  
18 different dates. I should probably have a  
19 better bookkeeping method than I do. But not  
20 yet.  
21 Q. In preparing for this  
22 deposition, did you look at anything to give  
23 you a sense of how much time you spent in May  
24 working on the report?

Page 91

1 A. Not explicitly.  
2 Q. What was the nature of the work  
3 that you did in May on your report on this  
4 estimated 20 to 30 hours?  
5 MS. MCENROE: Objection to  
6 form.  
7 A. From the period of May 30 until  
8 I filed the report, it would have been  
9 continuing to edit the manuscript or edit the  
10 report, going through performing additional  
11 analyses, reviewing materials that I relied  
12 on on the report, that sort of stuff.  
13 BY MR. PIFKO:  
14 Q. And did you work with others in  
15 drafting the report?  
16 A. I did.  
17 Q. And those are people who work  
18 at Analysis Group?  
19 A. That's correct.  
20 Q. Have you seen their invoices to  
21 counsel or Rite Aid?  
22 A. I saw invoices yesterday, but  
23 prior to that I'd never seen any invoices  
24 from them.

Page 92

1 Q. Okay. So you saw invoices from  
2 Analysis Group in preparing for this  
3 deposition?  
4 A. I saw invoices yesterday. My  
5 understanding is that a court order was --  
6 there's a court order to produce these  
7 invoices, and so yesterday was the first time  
8 I've ever seen any sort of invoice from  
9 Analysis Group to Rite Aid, much less any  
10 other client.  
11 Q. Did you work with anybody on  
12 the report who didn't work at Analysis Group?  
13 A. No.  
14 Q. After May 10th, or whenever the  
15 date that you finished your report, between  
16 then and now, did you do any work for the  
17 case?  
18 MS. MCENROE: Objection to  
19 form.  
20 A. Yes.  
21 BY MR. PIFKO:  
22 Q. What did you do?  
23 A. Primarily preparation for the  
24 deposition.

Page 93

1 Q. What did you do to prepare for  
2 the deposition?  
3 A. I did a few things. One is I  
4 went through my report multiple times so I  
5 could make sure that I could streamline the  
6 process of our discussion with relationship  
7 to the report.  
8 Two is I re-reviewed and  
9 re-reviewed again the materials that I rely  
10 on. I looked back at the analysis to make  
11 sure that I could explain it very clearly and  
12 succinctly if I'm asked about it.  
13 And that's about it. That's  
14 been the nature of my preparation.  
15 Q. Did you meet with counsel to  
16 prepare for the deposition?  
17 A. I did.  
18 Q. When was that?  
19 A. I met yesterday as well as last  
20 week, I believe. I met twice with them.  
21 Q. Yesterday, was that in person?  
22 A. Yes, that was in person.  
23 Q. Last week, was that in person?  
24 A. That was in person.

Page 94

1 Q. Was that here in Boston last  
2 week?  
3 A. That was here in Boston.  
4 Q. And was that -- those meetings  
5 with counsel that's present here today?  
6 A. Yes.  
7 Q. Anyone else?  
8 A. Last week counsel named Kelly  
9 Moore was here as well.  
10 Q. Okay. Yesterday she wasn't  
11 here?  
12 A. She was not here yesterday.  
13 Q. Did you speak with Kelly prior  
14 to meeting with her last week?  
15 A. I have spoken to her on the  
16 phone before.  
17 Q. Was there anyone else present  
18 at the meeting last week besides Kelly and  
19 counsel who is here today?  
20 A. Two members from Analysis Group  
21 were also present.  
22 Q. Who was that?  
23 A. Stephen Fink, and a woman named  
24 Erica VanSant, V-A-N-S-A-N-T.

Page 95

1 Q. Were Stephen and Erica at  
2 yesterday's meeting?  
3 A. They were at yesterday's  
4 meeting as well.  
5 Q. Anyone else?  
6 A. No.  
7 Q. So let's just be clear. So  
8 yesterday's meeting was Stephen, Erica, John,  
9 Elisa, and you?  
10 A. That's correct.  
11 Q. Okay. And last week was  
12 Stephen, Erica, Kelly. Was Elisa there?  
13 A. Elisa was there, but John was  
14 not there last week.  
15 Q. Okay. Did you have any other  
16 in-person meetings with counsel --  
17 A. No.  
18 Q. -- at any time on the case?  
19 A. Yes, we met once before. That  
20 was probably two months ago in Boston.  
21 Q. Who was present at that  
22 meeting?  
23 A. At that meeting was Elisa  
24 McEnroe and Kelly Moore.

Page 96

1 Q. Was there anyone from Analysis  
2 Group at that meeting?  
3 A. At that meeting, the same  
4 individuals were present as I just described.  
5 Q. Stephen and Erica?  
6 A. Yes.  
7 Q. The materials you relied upon  
8 in forming your opinions, so some of them are  
9 publicly available materials, some might be  
10 materials that you're aware of from your  
11 academic experience, but other materials are  
12 from the litigation, correct?  
13 A. That's correct.  
14 Q. Okay. How did you obtain the  
15 materials from the litigation?  
16 A. I formulated an outline of what  
17 I wanted to address in the report, and asked  
18 my colleagues that I supervise at Analysis  
19 Group to identify documents -- they were all  
20 available to them -- to identify documents  
21 that could help elucidate each one of those  
22 different points that I wanted to address.  
23 Q. So looking back to Exhibit 2,  
24 the second-to-last page, which is March,

Page 97

1 2019, time, item 4 says there's work on an  
2 outline.  
3 Do you see that?  
4 A. I see that.  
5 Q. Okay. Is that the outline that  
6 you're talking about?  
7 A. That is the outline -- I  
8 presume that's the outline that I'm talking  
9 about.  
10 Q. So you put together -- at that  
11 point you understood what the scope of your  
12 assignment was going to be?  
13 MS. MCENROE: Objection to  
14 form.  
15 A. I'm assuming that when I write  
16 here work on the outline, I'm referring to  
17 the first instance in which I'm working on  
18 it. It's possible that there may be other  
19 times that I was working on it. But let's --  
20 I'm estimating that it was around March 22nd,  
21 last week of March, and at that time I would  
22 have had a good understanding what my  
23 assignment would be.  
24 BY MR. PIFKO:

Page 98

1 Q. Okay. And you would have  
2 understood that your scope of your assignment  
3 was those three areas that we discussed  
4 earlier; assessing Dr. McCann, looking at  
5 Rite Aid's diversion control programs, and  
6 the harm potentially caused by Rite Aid?  
7 A. That's correct.  
8 MS. MCENROE: Objection to  
9 form.  
10 BY MR. PIFKO:  
11 Q. And so then you would have  
12 outlined the details of what you wanted to  
13 say in your report, and then asked people at  
14 Analysis Group to find you documents that are  
15 relevant to those issues?  
16 MS. MCENROE: Objection to  
17 form.  
18 A. I would have outlined  
19 details -- I'll just use your words to be  
20 specific. I would have outlined details of  
21 my report and asked Analysis Group to build  
22 out that information with me using evidence  
23 that's been produced in this litigation, my  
24 own research, and outside documents that are

Page 99

1 publicly available.  
2 But prior to that, as you can  
3 see, I'd been doing some work in this space  
4 and, you know, understood that these are  
5 likely to be the issues even without a formal  
6 assignment from counsel.  
7 And so the Analysis Group team  
8 has been familiarizing themselves through my  
9 direction of a lot of the material, including  
10 the data. I mentioned earlier that the ARCOS  
11 data is this huge dataset. It takes effort  
12 to understand, to debug, to analyze. That  
13 kind of analysis was already underway.  
14 By the end of March is when I  
15 had a firm direction of which way the report  
16 would go, and so some of the preparatory work  
17 that had already been done could now be  
18 really done in earnest. And so I asked the  
19 Analysis Group team to look into items A, B,  
20 C, and D and try to help me build out the  
21 evidence base for these different points.  
22 Q. Who gave you the firm direction  
23 about which way the report was going to go?  
24 MS. MCENROE: Objection to

Page 100

1 form.  
2 A. You mean specific on my  
3 language? The direction of the report was my  
4 direction. The assignment came from counsel.  
5 BY MR. PIFKO:  
6 Q. When you say the assignment  
7 versus the direction, what do you mean by  
8 that?  
9 A. Well, the assignment is a set  
10 of topics to answer. The direction of the  
11 report is up to me. I can analyze it using  
12 publicly available information. I can  
13 analyze it using ARCOS data. I can analyze  
14 these questions using documents that are  
15 produced in litigation. That's under my  
16 direction. Which is a different question  
17 than what is the questions that I'd like --  
18 counsel would like me to opine upon.  
19 Q. Okay. So when we talk about  
20 the three areas of assessing Dr. McCann, the  
21 quality of Rite Aid's diversion control  
22 programs, and the potential harm caused by  
23 Rite Aid, those came from counsel?  
24 MS. MCENROE: Objection to

Page 101

1 form.  
2 A. That is correct.  
3 BY MR. PIFKO:  
4 Q. Were there any other topics  
5 they asked you to look at that you decided  
6 not to use in your report?  
7 MS. MCENROE: Objection to  
8 form.  
9 A. No.  
10 BY MR. PIFKO:  
11 Q. Who did you work with at  
12 Analysis Group?  
13 A. I worked with a team. The team  
14 is led by Stephen Fink and Erica VanSant.  
15 There's a few other research assistants and  
16 associates who have also been involved in the  
17 work as well.  
18 Q. Let's discuss some of the  
19 people at Analysis Group. In order to do  
20 that, I'm going to hand you the materials I  
21 was provided yesterday from Analysis Group.  
22 MS. MCENROE: Mark, just to  
23 speed things along, those are  
24 organized in the same way the other

<p style="text-align: right;">Page 102</p> <p>1 documents had been.</p> <p>2 MR. PIFKO: Let's take a break</p> <p>3 so that we can organize these.</p> <p>4 THE VIDEOGRAPHER: The time is</p> <p>5 12:59 a.m., and we're off the record.</p> <p>6 (Whereupon, a luncheon recess</p> <p>7 was taken.)</p> <p>8</p> <p>9</p> <p>10</p> <p>11</p> <p>12</p> <p>13</p> <p>14</p> <p>15</p> <p>16</p> <p>17</p> <p>18</p> <p>19</p> <p>20</p> <p>21</p> <p>22</p> <p>23</p> <p>24</p>	<p style="text-align: right;">Page 104</p> <p>1 description.</p> <p>2 So in many antitrust cases, one</p> <p>3 of the key issues is defining the market, and</p> <p>4 the reason supported to define the market is</p> <p>5 to understand whether the firm has market</p> <p>6 power in that market. And it's actually not</p> <p>7 a trivial exercise to figure out what are the</p> <p>8 different products that comprise the market.</p> <p>9 So, for instance, Levi jeans</p> <p>10 and Lee jeans probably comprise the same</p> <p>11 market, whereas some fancy company, some</p> <p>12 fancier jeans may be in a different market.</p> <p>13 In the pharmaceutical context,</p> <p>14 the opinion that I provided in this</p> <p>15 particular case was trying to use a clinical</p> <p>16 perspective, clinical and economic</p> <p>17 perspective, to define the market.</p> <p>18 And I basically relied on</p> <p>19 clinical guidelines to say what would</p> <p>20 physicians who are faced with a patient who</p> <p>21 has condition X, what are the treatments that</p> <p>22 they would choose between, is it just one</p> <p>23 treatment, two treatments, which would have a</p> <p>24 narrow market, or is it seven or eight</p>
<p style="text-align: right;">Page 103</p> <p>1 AFTERNOON SESSION</p> <p>2</p> <p>3 THE VIDEOGRAPHER: The time is</p> <p>4 1:29 p.m., and we're on the record.</p> <p>5 BY MR. PIFKO:</p> <p>6 Q. Real quick before we go back to</p> <p>7 the invoices, I want to look at Exhibit 1</p> <p>8 again, your list of testimony.</p> <p>9 A. Yes.</p> <p>10 Q. Are you there?</p> <p>11 A. Yes.</p> <p>12 Q. What were your opinions in the</p> <p>13 antitrust case?</p> <p>14 MS. MCENROE: Objection to</p> <p>15 form.</p> <p>16 And I'm not familiar with that</p> <p>17 litigation, so I don't know if there</p> <p>18 are confidentiality provisions in</p> <p>19 place or a protective order. So I</p> <p>20 just warn, if Dr. Jena believes it's</p> <p>21 confidential, that he shouldn't</p> <p>22 testify to that. But otherwise I</p> <p>23 don't have any basis to say otherwise.</p> <p>24 A. I can give you a high-level</p>	<p style="text-align: right;">Page 105</p> <p>1 treatments, which would imply a broader</p> <p>2 market.</p> <p>3 And then I conducted data</p> <p>4 analysis to look at real world patients and</p> <p>5 to see in those contexts, what are the types</p> <p>6 of drugs that patients choose between, do</p> <p>7 they choose between one or two patients,</p> <p>8 again, which would define the market to be</p> <p>9 narrower, or do they choose between eight or</p> <p>10 nine medications.</p> <p>11 So that's the kind of basic</p> <p>12 analysis that I performed there.</p> <p>13 BY MR. PIFKO:</p> <p>14 Q. Okay. And then ultimately your</p> <p>15 conclusion was that your clients did not have</p> <p>16 market power?</p> <p>17 MS. MCENROE: Objection to</p> <p>18 form.</p> <p>19 A. In this particular case I</p> <p>20 didn't actually come down on market power</p> <p>21 versus not. I was really defining the market</p> <p>22 and looking at economic substitutability.</p> <p>23 So the specific conclusion that</p> <p>24 I had in this particular paper was looking at</p>

<p style="text-align: right;">Page 106</p> <p>1 whether or not the product at issue was an  2 economic or therapeutic substitute with other  3 products. And the way I did that is I said,  4 look at other treatment -- look at treatment  5 guidelines and see whether or not there are  6 other products or not. If there are, then  7 there would be substitutes towards that first  8 product.  9 And then the second issue is  10 looking at how patients' demand for the first  11 product at issue relates to the prices of  12 other products. If there's a cross-price  13 elasticity, meaning a sensitivity of demand  14 of the first product with respect to the  15 other ones, that would suggest that there  16 might be economic substitutes.  17 So that's what I was opining  18 on, is there economic or clinical  19 substitutability between an at-issue product  20 and the other ones.  21 Q. Okay. Did you find that there  22 was economic substitutability for your  23 clients' products?  24 MS. MCENROE: Objection to</p>	<p style="text-align: right;">Page 108</p> <p>1 here, it was a very similar issue of what are  2 the therapeutic substitutes to the product.  3 In this case it was a product to treat  4 metabolic disease. And the question was  5 whether or not there are other products that  6 are used to treat metabolic disease, or  7 simply one product.  8 BY MR. PIFKO:  9 Q. And did you find that your  10 clients' -- there was substitutability for  11 your clients' products in this -- in the  12 arbitration case as well?  13 MS. MCENROE: Objection to  14 form.  15 A. In that case I found that there  16 are other treatment options that are  17 supported by clinical guidelines for the  18 treatment of this particular condition.  19 BY MR. PIFKO:  20 Q. Okay. And then the Amphastar  21 case, what was the nature of your opinions?  22 MS. MCENROE: Objection to  23 form. Same objection I made  24 previously regarding confidentiality</p>
<p style="text-align: right;">Page 107</p> <p>1 form.  2 A. In this case I found that  3 there's clinical and economic  4 substitutability between that product and  5 other products.  6 THE VIDEOGRAPHER: Can we go  7 off for one second? I don't know --  8 something got tripped with the power.  9 It seems -- now it's back. Sorry.  10 BY MR. PIFKO:  11 Q. Okay. Going to the Ranbaxy  12 case, what was the nature of your opinions in  13 that case?  14 MS. MCENROE: Objection to  15 form. Same objection I made  16 previously regarding potential  17 confidentiality concerns.  18 But, Dr. Jena, I leave that to  19 you in terms of whether you have a  20 protective order obligation or not.  21 A. I think I can provide a  22 high-level analysis. I wish I remembered  23 more of the details of the case.  24 But in this particular case</p>	<p style="text-align: right;">Page 109</p> <p>1 obligations or a protective order, but  2 I leave that up to the witness.  3 A. That was a similar sort of case  4 where I was approaching this question to  5 define the market from a clinical  6 perspective. This was a -- also a  7 cardiovascular medication that was at issue  8 here. And the question was whether or not  9 that medication is the only medication that  10 patients use for this particular condition,  11 or do clinical guidelines assert five or six  12 different medications.  13 And my finding there was that  14 there's multiple different medications that  15 physicians use.  16 BY MR. PIFKO:  17 Q. Okay. So similarly, there was  18 substitutability for those -- your clients'  19 product as well?  20 MS. MCENROE: Objection to  21 form.  22 A. That's correct. Another way to  23 say it is that the product is not unique in  24 any particular way.</p>



Page 110

1 BY MR. PIFKO:  
2 Q. Okay. Do you know -- in all  
3 these cases, was your client a plaintiff or  
4 defendant? Do you know the answer to that?  
5 A. In these two cases, I was  
6 representing the defendant.  
7 Q. Okay. In all three, they were  
8 defendants?  
9 A. That's correct.  
10 (Whereupon, Jena Exhibit Number  
11 3 was marked for identification.)  
12 BY MR. PIFKO:  
13 Q. I'm handing you what's marked  
14 as Exhibit 3.  
15 A. Thank you.  
16 Q. These are invoices from  
17 Analysis Group that I received yesterday.  
18 Take a moment to review them real quick, and  
19 let me know when you're ready.  
20 MR. PIFKO: For the record,  
21 there are several pages within, but there's  
22 one dated May 24, 2018, July 3, 2018,  
23 July 27, 2018, August 20, 2018, September 28,  
24 2018, October 22, 2018, December 21, 2018,

Page 111

1 January 25, 2019, February 19, 2019,  
2 March 22, 2019, April 29, 2019, and May 21,  
3 2019.  
4 (Witness reviewing document.)  
5 A. Okay. I've reviewed them.  
6 BY MR. PIFKO:  
7 Q. Okay. So the first time that  
8 you saw these was yesterday?  
9 A. The first time that I saw an  
10 invoice was yesterday. I haven't reviewed  
11 all -- you know, multiple of these invoices  
12 here.  
13 Q. So you don't have any knowledge  
14 either way about whether these are true and  
15 correct and accurate?  
16 A. To the extent that they reflect  
17 my own professional hours and those are  
18 consistent with what's reported in the  
19 spreadsheet, those are an accurate reflection  
20 of my work in this matter. I don't -- I'm  
21 not involved in the billing of Analysis Group  
22 for its own work and services to clients,  
23 including Rite Aid.  
24 Q. Okay. So you don't know if --

Page 112

1 for example, looking at the top invoice from  
2 May 24, 2018, the second page, it's got two  
3 hours of time for Stephen Fink.  
4 Do you see that?  
5 A. Yes, I see that on the second  
6 page.  
7 Q. So you don't know if that's  
8 accurate or not, correct?  
9 A. I'm not an accountant, and also  
10 I'm not filling this invoice, so I can't say  
11 if it's accurate or not. I presume that it's  
12 accurate, but it's an invoice that I wasn't  
13 part of.  
14 Q. Okay. But your time -- we can  
15 cross-check your time with Exhibit 2 and see  
16 that, if you look at the first page of  
17 Exhibit 2, April 27, 2018, you billed  
18 25 hours, we can see that that is correct,  
19 yes?  
20 A. Yes.  
21 Q. Okay. And you don't have a  
22 date -- there isn't a date on the Analysis  
23 Group invoice, but it's for the period that  
24 ends April 30th, so we can conclude that that

Page 113

1 .5 is the .5 referenced in your --  
2 MS. MCENROE: Objection to  
3 form.  
4 BY MR. PIFKO:  
5 Q. -- April 27, 2018 invoice,  
6 correct?  
7 A. I would think so.  
8 Q. So other than verifying your  
9 time like we just did for the April 30, 2018  
10 period, you're not able to verify the  
11 accuracy of any of these Analysis Group  
12 invoices, correct?  
13 MS. MCENROE: Objection to  
14 form.  
15 A. I can't comment on the accuracy  
16 of any billing besides my own.  
17 BY MR. PIFKO:  
18 Q. Who would be the best person to  
19 do that? Mr. Fink?  
20 MS. MCENROE: Objection to  
21 form.  
22 A. I also don't know who the best  
23 person at Analysis Group would be to do that.  
24

Page 114

1 BY MR. PIFKO:  
2 Q. Okay. But we'd have to talk to  
3 someone at Analysis Group?  
4 MS. MCENROE: Objection to  
5 form.  
6 A. I presume so. It definitely  
7 wouldn't be to talk to me.  
8 BY MR. PIFKO:  
9 Q. I do want to go through,  
10 however, some of these, and ask you about the  
11 individuals.  
12 A. Sure.  
13 Q. So then go to the July 3, 2018  
14 invoice, and then you go to Page 3. Tell me  
15 when you're there.  
16 A. Okay. I am there.  
17 MS. MCENROE: I see.  
18 BY MR. PIFKO:  
19 Q. All right. So it's got you for  
20 nine hours. We can cross-check. That's  
21 consistent with the amount of time you  
22 billed, if you look back at Exhibit 2,  
23 correct?  
24 A. That looks like it's for the

Page 115

1 May period, in May, that looks correct, yes.  
2 Q. Okay. The next person,  
3 N. Kirson, do you know who that is?  
4 A. Yes.  
5 Q. What's their full name?  
6 A. Noam Kirson, N-O-A-M.  
7 Q. And is that a man or a woman?  
8 A. That's a man.  
9 Q. I assumed, but you never know.  
10 What does he do?  
11 A. He is also a vice president at  
12 Analysis Group.  
13 Q. Do you know what his background  
14 is?  
15 A. He has a PhD in economics from  
16 Harvard.  
17 Q. He's employed by Analysis  
18 Group?  
19 A. I believe so, yes.  
20 Q. Do you know if he has any other  
21 degrees?  
22 A. Besides the PhD? He might, but  
23 I'm not sure. He does not have an MD.  
24 Q. Did you work with him on this

Page 116

1 matter?  
2 A. I did.  
3 Q. What was the nature of your  
4 work with him?  
5 MS. MCENROE: Objection to  
6 form.  
7 A. This was a period, I believe,  
8 when Mr. Fink was out, or soon to be, on some  
9 abbreviated -- a paternity leave, he just had  
10 twins around this time. And Mr. Kirson was  
11 involved for some period of time, maybe a  
12 month or two, in kind of starting the work on  
13 this Rite Aid matter.  
14 BY MR. PIFKO:  
15 Q. Did you consult with him about  
16 strategies to use in the case?  
17 MS. MCENROE: Objection to  
18 form.  
19 A. I discussed with him what are  
20 the datasets that are currently being  
21 produced in the litigation.  
22 A lot of the early work in this  
23 matter that you're referencing in this time  
24 period would have been data-oriented.

Page 117

1 BY MR. PIFKO:  
2 Q. Okay. So the work with  
3 Mr. Kirson was limited to just this early  
4 period when Mr. Fink was on leave?  
5 A. We can go through the  
6 individual invoices just to verify, but we  
7 can see in the next invoice of July 27,  
8 Mr. Kirson's name is listed. August 20th,  
9 his name is no longer listed. September 28th  
10 invoice, his name is no longer listed.  
11 Q. I can represent to you I went  
12 through these. He's only billed time in  
13 May -- the May 28, 2018, and the June, 2018.  
14 A. That would be consistent with  
15 my recollection and also the explanation I  
16 just provided regarding the paternity leave  
17 for Mr. Fink.  
18 Q. Okay. We talked about Stephen  
19 Fink.  
20 Who is S. Kim?  
21 A. I believe that's Soojin Kim.  
22 Q. Mr. Fink, by the way, what --  
23 do you know what type of degrees he has?  
24 A. He has an MBA from Columbia

Page 118

1 Business School, and an undergraduate from  
2 Vassar College.  
3 Q. Soojin Kim, do you know the  
4 academic background?  
5 A. I don't know her detailed  
6 academic background. I believe she studied  
7 economics and is an undergraduate, may have  
8 an MBA or a master's degree, but I'm not  
9 entirely sure.  
10 Q. Did you work with Ms. Kim on  
11 the matter?  
12 A. I worked with all these  
13 individuals on the matter. Each person has  
14 different roles, and the roles vary over  
15 time, but I worked with each one of these  
16 individuals on the case.  
17 Q. What was Ms. Kim's role?  
18 A. It's hard to say as of this  
19 period what her role was, but I can outline  
20 for you the general roles that I oversaw.  
21 So one big thing is data  
22 cleaning, data preparation, data analysis.  
23 The second big thing would be  
24 analyzing existing documents that have been

Page 119

1 produced in the litigation, looking at  
2 publicly available documents, looking at  
3 publicly available data.  
4 The third broad bucket would be  
5 in terms of helping drafting particular  
6 sections of the report under my direction.  
7 For instance, I might say, you know, I've  
8 written this paper on XYZ, could you please  
9 put that into the report, cite this study,  
10 and describe it in the following way. And  
11 they would pull the report, introduce it --  
12 pull the study, introduce it into the record,  
13 so forth.  
14 So Ms. Kim, as well as  
15 including Mr. Fink, Mr. Kirson, and others  
16 that you'll see on subsequent invoices, would  
17 probably have all shared roles of those  
18 forms.  
19 Q. When you say "data cleaning,"  
20 what does that mean?  
21 A. Data cleaning means the  
22 following; if you get a large data set,  
23 sometimes the data elements aren't as  
24 structured as they should be.

Page 120

1 So, for instance, if you get a  
2 data set that's transaction-based and it says  
3 1/7/2012, you and I would probably both  
4 interpret that to mean January 7, 2012. The  
5 next line might say 1-7-2012. In order to  
6 analyze data in a systematic way, we have to  
7 tell the computer program that both of those  
8 entries reflect January 7, 2012. The process  
9 of data cleaning is one in which an analyst  
10 would go through and write a program to  
11 create a data set that can be easily  
12 analyzed.  
13 That's an example of what data  
14 cleaning, or data processing is the other  
15 term you might hear.  
16 Q. What type of data analysis did  
17 Ms. Kim do?  
18 MS. MCENROE: Objection to  
19 form.  
20 A. So in this particular case, the  
21 data analysis that were conducted -- and she  
22 was probably a part of some of this, but it's  
23 hard for me to know exactly what part. This  
24 is a report and a set of analysis that was

Page 121

1 conducted over many months over many person  
2 hours.  
3 The core parts of the empirical  
4 analysis in my report reflect the ARCOS  
5 database, which is a transaction database. I  
6 focused on opioid distribution, looking  
7 particularly at Dr. McCann's report in which  
8 he identified a methodology for flagging  
9 potentially suspicious orders.  
10 So I analyzed the database and  
11 said, look, there's five methodologies that  
12 Dr. McCann lays out, can we first replicate  
13 that methodology. That was the first task,  
14 can we replicate what Dr. McCann has done.  
15 And then, secondly, now let me  
16 start and kind of unpack what is the validity  
17 of each one of these methodologies. And  
18 doing that requires working with the ARCOS  
19 data. And that's, I'm sure, what Ms. Kim and  
20 Mr. Fink and Mr. Kirson and Mr. Flignor and  
21 others had a part in as well.  
22 Q. So I was going to ask you, the  
23 ARCOS data that you examined, are you aware  
24 that there's publicly available ARCOS data,

Page 122

1 then there's ARCOS data that was produced in  
2 the case?  
3 MS. MCENROE: Objection to  
4 form.  
5 A. I'm aware of that.  
6 BY MR. PIFKO:  
7 Q. Okay. Which ARCOS data did you  
8 review?  
9 A. The ARCOS -- there's two types  
10 of ARCOS data, actually, that I rely on in my  
11 report. The first is data that was produced  
12 in the case, and that expanded over time.  
13 Initially it was in these counties. It's  
14 actually national in nature.  
15 The second is a form that was  
16 processed by expert McCann, Dr. McCann.  
17 There, he had already processed some of the  
18 information. And in order to be consistent  
19 with his analysis and to ensure that his  
20 analysis was valid, I used the process data  
21 that Dr. McCann had used of the ARCOS data.  
22 Q. You said one of the steps in  
23 the process that you used was replicating the  
24 analysis that Dr. McCann did. Was your team

Page 123

1 able to do that?  
2 A. I was able to replicate quite  
3 closely his analysis. There's actually some  
4 issues in his analysis that I mention in the  
5 report.  
6 For example, in one of his  
7 methodologies, which is a methodology for  
8 comparing the current pharmacy distribution  
9 to an average in the last several months, his  
10 methodology states that he uses the averages  
11 nationally. In fact, there's a coding error  
12 that I and my team uncovered. He actually  
13 only used the averages in the state -- the  
14 counties at issue here, Cuyahoga and Summit.  
15 So, for the most part, I would  
16 say that I was able to replicate his  
17 analysis. That's not a -- that's not a  
18 statement of whether I think his analysis is  
19 valid. It could be replicated somewhat. But  
20 it's a separate issue of whether I think that  
21 analysis is correct. And I go to great  
22 lengths in the report to say that I don't  
23 think it is.  
24 Q. Okay. Mr. Flignor -- did I say

Page 124

1 that name right?  
2 A. I believe so.  
3 Q. Okay. What's his full name?  
4 A. I believe it's Max Flignor, but  
5 there's two Maxes, I think, that I've worked  
6 with in this case, but...  
7 Q. Do you know what his background  
8 is?  
9 A. I believe an undergraduate  
10 degree, probably in economics or mathematics  
11 or statistics.  
12 Q. Do you know from where?  
13 A. I don't know from where, no.  
14 Q. What was his role?  
15 A. He had -- he would have had a  
16 similar role as Ms. Kim. In general, as you  
17 go through the invoices, the analysts and  
18 senior analysts all have quite similar roles,  
19 analyzing data, culling through documents,  
20 synthesizing information, all under my  
21 direction.  
22 Q. Let's go to -- a new name shows  
23 up in the July 27, 2018 invoice. Tell me  
24 when you're there. Page 3 of that invoice.

Page 125

1 A. Yes.  
2 Q. Okay. Again, we can  
3 cross-check your time with Exhibit 2. You  
4 billed 11 hours in June. Does that match up  
5 with your time in June on your time from  
6 Exhibit 2?  
7 A. That does match up, yes.  
8 Q. Okay. So the last name is  
9 Briesemeister?  
10 A. Briesemeister.  
11 Q. Briesemeister.  
12 A. Joe.  
13 Q. Joe.  
14 What does Joe do?  
15 A. Joe has a very similar role to  
16 both Soojin and Mr. Flignor as an analyst or  
17 senior analyst, in this case he's an analyst,  
18 same types of tasks I just outlined.  
19 Q. Do you know what his background  
20 is?  
21 A. I believe also an undergraduate  
22 degree.  
23 Q. You don't know in what?  
24 A. I think either economics or



<p style="text-align: right;">Page 126</p> <p>1 statistics. Most of the analysts and senior  2 analysts at Analysis Group and other similar  3 firms have an undergraduate degree in  4 economics or statistics.  5 Q. If you go about halfway  6 through, the December 21, 2018 invoice --  7 tell me when you're there.  8 A. I'm there.  9 Q. Okay. Then go to Page 2.  10 We see Erica VanSant's name?  11 A. Yes.  12 Q. You mentioned her earlier?  13 A. Yes.  14 Q. What was her role?  15 A. She's an associate in Analysis  16 Group. She has a PhD in economics from  17 Carnegie Mellon University. She had a very  18 similar role as Stephen Fink, overseeing some  19 of the senior analysts and analysts that were  20 involved in those tasks that I outlined.  21 Q. Okay. So she was overseeing  22 some of the other analysts?  23 A. That's correct, along with  24 Mr. Fink.</p>	<p style="text-align: right;">Page 128</p> <p>1 is my report. I edited it heavily. The  2 language that you see there, that's my  3 language.  4 BY MR. PIFKO:  5 Q. Go to the April 29, 2019  6 invoice. Go to Page 3. Tell me when you're  7 there.  8 A. I'm there.  9 Q. All right. So then we see some  10 additional names show up here.  11 M. Lewis. Is that Max Lewis?  12 A. Mark Lewis.  13 Q. Okay. What does Mark Lewis do?  14 A. Mark is a vice president at  15 Analysis Group. He has a background in  16 economics. He's been an economic litigation  17 consultant for many years. He was involved  18 in helping Ms. Fink -- Mr. Fink and  19 Ms. VanSant.  20 Q. For what specifically was he  21 doing helping them?  22 A. Also similar project oversight.  23 This is a period -- as you can see,  24 March 31st, my own time now becomes more</p>
<p style="text-align: right;">Page 127</p> <p>1 Q. She had more involvement in  2 your report than some of the other people?  3 You brought her with you to the meetings?  4 MS. MCENROE: Objection to  5 form.  6 A. She has had a role in my report  7 as a leadership role within Analysis Group,  8 along with Mr. Fink.  9 BY MR. PIFKO:  10 Q. Did she draft some portions of  11 the report as well?  12 MS. MCENROE: Objection to  13 form.  14 A. The report as you see it is my  15 report. I drafted a large part of it. There  16 are certain portions which I thought were  17 fairly straightforward for someone who  18 doesn't need to have a PhD and MD to draft.  19 And so for those portions, Mr. Fink,  20 Ms. VanSant would probably have been doing  21 some of the drafting. It's possible that  22 some of the other analysts would have also  23 been doing the drafting.  24 But at the end of the day, this</p>	<p style="text-align: right;">Page 129</p> <p>1 considerable. This is the part of the  2 invoices where I'm starting to work in  3 earnest on the report.  4 And now you can see that the  5 team has increased in size to make sure that  6 all the different analyses that I'm  7 suggesting are getting done in a timely way,  8 can be ready to be prepared by the May 10th  9 filing.  10 Q. Do you know if Mr. Lewis  11 drafted any portions of the report?  12 MS. MCENROE: Objection to  13 form.  14 A. Mr. Lewis, Mr. Fink, and  15 Ms. VanSant would have been involved under my  16 direction at portions of drafting.  17 BY MR. PIFKO:  18 Q. We see another name,  19 D. Kellachan.  20 A. Dylan.  21 Q. Dylan?  22 A. D-Y-L-A-N.  23 Q. Is that a woman?  24 A. That's a man.</p>



Page 130

1 Q. Okay. What's his background?  
 2 A. He also has a background in  
 3 economics, I believe a master's degree, and  
 4 also experienced in litigation economic work.  
 5 Q. And what was his role?  
 6 A. Same type of role as Erica  
 7 VanSant.  
 8 Q. A management oversight role?  
 9 A. Management, yeah. I mean,  
 10 they -- I would describe it in the following;  
 11 senior analysts and analysts are doing much  
 12 more of the data analysis and data  
 13 processing. Associates and vice-presidents  
 14 have a similar role. There is management of  
 15 the analysts, but they're also involved in  
 16 double checking, and then in my case also  
 17 triple checking.  
 18 The idea here is this report  
 19 has got to be thorough, it's got to be done  
 20 in a way that meets the academic standards  
 21 that I have. I'm signing my name to it, and  
 22 so I want to make sure each one of these  
 23 people is doing exactly what I tell them to  
 24 do -- ask them to do for the report.

Page 131

1 (Whereupon, Jena Exhibit Number  
 2 4 was marked for identification.)  
 3 BY MR. PIFKO:  
 4 Q. I'm handing you what's marked  
 5 as Exhibit 4.  
 6 A. Thank you.  
 7 Q. Take a moment to review that.  
 8 Let me know when you're done.  
 9 A. This is my report.  
 10 Q. All right. First question, can  
 11 you tell me what Exhibit 4 is?  
 12 A. Exhibit 4 is my report.  
 13 Q. Okay. And to be clear, it's --  
 14 the appendices are not included as part of  
 15 Exhibit 4.  
 16 Other than the appendices, does  
 17 Exhibit 4 reflect all the work that you did  
 18 in forming your opinions in this case?  
 19 MS. MCENROE: Objection to  
 20 form.  
 21 A. Exhibit 4 reflects my opinions.  
 22 The materials that I considered in the report  
 23 are listed in the appendix. That includes  
 24 documents produced in litigation, outside

Page 132

1 documents that are publicly available, and,  
 2 of course, my experience as a physician, as a  
 3 health policy researcher, as an economist,  
 4 those comprise the opinion.  
 5 Q. Did you consider anything else  
 6 outside of what you just said and what's in  
 7 your report in forming your opinions?  
 8 MS. MCENROE: Objection to  
 9 form.  
 10 A. No.  
 11 BY MR. PIFKO:  
 12 Q. Is Exhibit 4 a true and correct  
 13 copy of your report?  
 14 MS. MCENROE: Objection to  
 15 form.  
 16 Do you want him to go through  
 17 page by page?  
 18 A. Exhibit 4 appears to be a true  
 19 and accurate reflection of my report.  
 20 BY MR. PIFKO:  
 21 Q. Okay. Does Exhibit 4 reflect  
 22 all the opinions that you intend to provide  
 23 in this case?  
 24 MS. MCENROE: Objection to

Page 133

1 form.  
 2 A. Exhibit 4 reflects the opinions  
 3 that I provided to date. I reserve the right  
 4 to provide additional opinions should  
 5 additional information surface, or if I'm  
 6 asked by counsel to opine on other issues.  
 7 BY MR. PIFKO:  
 8 Q. Do you intend to perform  
 9 additional work after this deposition --  
 10 MS. MCENROE: Objection to  
 11 form.  
 12 BY MR. PIFKO:  
 13 Q. -- on this case?  
 14 A. I have no plan or intention to  
 15 perform additional work on this case. If I'm  
 16 asked to do so, I may choose to do so. But  
 17 as of now, I have no firm intention of doing  
 18 that.  
 19 Q. Has counsel asked you to do any  
 20 additional work on the case in connection  
 21 with your report?  
 22 MS. MCENROE: Objection to  
 23 form.  
 24 A. No further work has been

Page 134

1 requested of me for this case.  
2 BY MR. PIFKO:  
3 Q. Is there anything that's  
4 missing or incomplete from your report that  
5 you need to finish after -- as of this date?  
6 A. No. This report is complete as  
7 you have it.  
8 Q. Can you summarize your opinions  
9 for me?  
10 A. Sure.  
11 So let me point you to the  
12 right page so you can see where I'm going to  
13 be talking to you from. So if you start at  
14 Page 4, it outlines the beginning of the  
15 Summary of Conclusions.  
16 So basically there's four main  
17 conclusions.  
18 The first conclusion is that  
19 Rite Aid, Mid-Atlantic as a distributor, in  
20 my opinion, had in place effective  
21 anti-diversion measures as a distributor.  
22 That's the first opinion.  
23 The second is, if you look at  
24 Dr. McCann's methodology, my view is this is

Page 135

1 a methodology for identifying suspicious  
2 orders, the methodology is flawed. And I'm  
3 happy to walk through why it is the case if  
4 you'd like.  
5 Third is from the perspective  
6 of whether or not there's any harm caused by  
7 diversion of opioids from Rite Aid  
8 pharmacies. I find no evidence of any harm  
9 arising from diversion of opioids from Rite  
10 Aid pharmacies.  
11 And the fourth is that -- is an  
12 important point, that the plaintiffs'  
13 experts' reports don't characterize  
14 Rite Aid's role as a distributor in the way  
15 that I think that we should be characterizing  
16 distributors and separating the role of  
17 distributors from pharmacists, from  
18 physicians. And the interplay of the opioid  
19 epidemic that we're in right now is a  
20 complicated one, and it relies on many  
21 different factors.  
22 And the last part of my opinion  
23 is that we cannot ignore the role of  
24 prescribers in the epidemic. And there's a

Page 136

1 section of my report that goes through that  
2 in more detail.  
3 Q. Did Rite Aid's counsel draft  
4 any portions of the report?  
5 MS. MCENROE: Objection to  
6 form.  
7 And I instruct you, in terms of  
8 substantive discussions with counsel,  
9 that is privileged, and you should not  
10 respond.  
11 In terms of mechanics of your  
12 report, I'm not trying to stop you  
13 from responding, but I recognize that  
14 there's a fine line there, so I ask  
15 you not to divulge privileged  
16 information.  
17 A. This is my report. I and my  
18 team drafted it, not the counsel.  
19 BY MR. PIFKO:  
20 Q. So they had no involvement in  
21 drafting it? Is that your testimony, just to  
22 be clear?  
23 MS. MCENROE: Objection to  
24 form.

Page 137

1 A. Counsel has reviewed the report  
2 but did not write sentences or tell me to say  
3 one thing or the other.  
4 Just to be very clear, the  
5 opinions in this report, these are my  
6 opinions. The direction that the report  
7 took, that was my direction.  
8 BY MR. PIFKO:  
9 Q. You said that if you became  
10 aware of additional information, you maybe  
11 would revisit your opinions. Did I hear you  
12 correctly?  
13 MS. MCENROE: Objection to  
14 form.  
15 A. If there's any information that  
16 is brought to my attention that contradicts  
17 portions of my report, I suppose that I'd be  
18 willing to look at that and consider that. I  
19 have no intention at all of being involved in  
20 this case any further beyond this. If I'm  
21 asked to do something, an assignment, I will  
22 consider it at that time. But right now,  
23 what you have in front of you, this report,  
24 is my plan.

<p style="text-align: right;">Page 138</p> <p>1 BY MR. PIFKO:  2 Q. All my question was going to be  3 was, if you were aware of any information  4 that potentially contradicts your report that  5 you intend to look at?  6 A. Oh, absolutely not. I'm not  7 aware of any such information.  8 Q. Do you intend to provide any --  9 do you intend to testify at trial if there's  10 a trial in this case?  11 A. If I'm asked to testify at  12 trial, then I suspect I would be able and  13 willing to testify at trial.  14 Q. Okay. And Exhibit 4 reflects a  15 complete set of the opinions that you would  16 provide at trial, correct?  17 MS. MCENROE: Objection to  18 form.  19 A. This provides my opinions to  20 date. If any new information is produced  21 from now until then, I would reserve the  22 right to analyze an opinion and give my  23 unbiased opinion.  24 BY MR. PIFKO:</p>	<p style="text-align: right;">Page 140</p> <p>1 opinion, might be useful to illustrate the  2 opinions in my report.  3 BY MR. PIFKO:  4 Q. Let's look at some of the  5 appendices that you provided.  6 (Whereupon, Jena Exhibit Number  7 5 was marked for identification.)  8 BY MR. PIFKO:  9 Q. Handing you what's marked as  10 Exhibit 5.  11 A. Thanks.  12 Q. Take a minute to look at  13 Exhibit 5, and let me know when you're done.  14 A. I'm done.  15 Q. Okay. Can you tell me what  16 Exhibit 5 is?  17 A. Sure. So Exhibit 5 reflects an  18 analysis that I conducted which is called a  19 falsification analysis. The idea behind a  20 falsification analysis -- and I have a paper  21 published on this in the Journal of Medical  22 Research, which is MICV.  23 The basic idea behind the  24 falsification analysis is to see whether some</p>
<p style="text-align: right;">Page 139</p> <p>1 Q. But other than new information  2 that doesn't exist as of today, Exhibit 4  3 represents the opinions that you would  4 provide at trial, correct?  5 A. That is --  6 MS. MCENROE: Objection to  7 form.  8 A. I apologize.  9 That is correct.  10 BY MR. PIFKO:  11 Q. Other than the people at  12 Analysis Group that we discussed, did you  13 talk to anyone else about your report?  14 A. No.  15 Q. Did you talk about your report  16 or your opinions with any other academic  17 colleagues?  18 A. No.  19 Q. If you testify at trial, do you  20 intend to provide any demonstrative exhibits?  21 MS. MCENROE: Objection to  22 form.  23 A. I would reserve the right to do  24 that. Probably some of the exhibits, in my</p>	<p style="text-align: right;">Page 141</p> <p>1 of the patterns that Dr. McCann outlined as  2 being -- as flagging -- let me use the word  3 "potentially suspicious" because other  4 plaintiffs' experts used the report in that  5 way.  6 The question is whether or not  7 the methodology that he uses for flagging  8 orders is legitimate. One sign that the  9 analysis would not be legitimate or valid  10 scientifically is, if you can generate the  11 same sorts of patterns using drugs that are  12 not addictive, that don't cause harm in the  13 way that opioids do, and that have no street  14 value.  15 So if you're able to generate  16 the same findings with non-opioid drugs, that  17 should raise a red flag as to whether or not  18 the primary methodology that you're using, in  19 this case Dr. McCann, is valid. So Appendix  20 E presents 80 plots that are basically  21 store-by-store analyses of figures that are  22 in the report.  23 And in the report, what I  24 basically show is that the patterns that</p>

Page 142

1 Dr. McCann shows with opioids, that he and  
 2 then other plaintiffs' experts suggest is  
 3 illustrative of suspicious ordering,  
 4 suspicious distribution, those same patterns  
 5 occur when you look at drugs like  
 6 levothyroxine, that's a very common thyroid  
 7 medication, metoprolol succinate, that's a  
 8 beta blocker medication for heart disease,  
 9 statins, cholesterol medications, amlodipine,  
 10 which is a calcium channel blocker to treat  
 11 hypertension, you see the exact same patterns  
 12 with these other drugs as you see with  
 13 opioids.  
 14 So that to me is strong  
 15 evidence that whatever Dr. McCann is doing  
 16 when he's trying to, quote/unquote, flag  
 17 orders in opioids one could very easily  
 18 replicate with other very standard drugs.  
 19 And, by the way, these drugs  
 20 are very standard. I chose these drugs  
 21 because during this period, I think in 2006,  
 22 they are the top three or four selling drugs  
 23 in the market at the time. So these aren't  
 24 cherry-picked in any way. Appendix E

Page 143

1 basically takes the plots that are in the  
 2 report and does it store by store.  
 3 That's a long-winded way to  
 4 describe what Appendix E is.  
 5 Q. Okay. And did someone at  
 6 Analysis Group actually prepare these charts?  
 7 A. Someone at Analysis Group  
 8 prepared these charts under my direction.  
 9 And this was my idea, by the way. I publish  
 10 on falsification tests, and so I said to the  
 11 team, we've got to show this. In order to  
 12 say that this methodology is not robust,  
 13 meaning Dr. McCann's methodology, I want to  
 14 be able to take the best academic evidence  
 15 that there is and the best academic  
 16 approaches and look at it in this way. And  
 17 this is just a very transparent way -- it's a  
 18 lengthy way, but it's a transparent way to  
 19 show that.  
 20 Q. Are there any -- did you say  
 21 falsification tests? Is that what they're  
 22 called?  
 23 A. That's what they're called,  
 24 yes.

Page 144

1 Q. Okay. Are there any  
 2 falsification tests that you performed on  
 3 other products that you didn't end up  
 4 including in your report?  
 5 A. No. These were the products  
 6 that were analyzed. The reason I chose them  
 7 is because they were the top-selling drugs in  
 8 the period at issue.  
 9 Q. Did you perform any other  
 10 analysis of data that you didn't include in  
 11 your report?  
 12 MS. MCENROE: Objection to  
 13 form.  
 14 A. All the analysis of data that I  
 15 performed is in this report.  
 16 (Whereupon, Jena Exhibit Number  
 17 6 was marked for identification.)  
 18 BY MR. PIFKO:  
 19 Q. Handing you what's marked as  
 20 Exhibit 6.  
 21 A. Thank you.  
 22 MS. MCENROE: Thank you.  
 23 BY MR. PIFKO:  
 24 Q. Take a minute to review that,

Page 145

1 and let me know when you're done.  
 2 A. Okay. I'm done.  
 3 Q. Can you tell me what Exhibit 6  
 4 is?  
 5 A. Sure. Exhibit 6 reflects  
 6 Appendix D, which is an appendix in my report  
 7 which I just very briefly summarize  
 8 plaintiffs' experts' reports mentioning Rite  
 9 Aid.  
 10 Q. And what does Exhibit 6 tell me  
 11 about other reports?  
 12 MS. MCENROE: Objection to  
 13 form.  
 14 A. It does two things. First, it  
 15 just gives you a very high-level summary of  
 16 the expert assignment or opinion in each one  
 17 of the reports. That's the third column.  
 18 And then it identifies whether or not Rite  
 19 Aid was mentioned in the report, either  
 20 identified as a defendant, which is the  
 21 third-to-last column, or included in the  
 22 materials considered, which is the  
 23 second-to-last column.  
 24 BY MR. PIFKO:



Page 146

1 Q. Did you prepare Exhibit 6?  
2 A. I asked the team to prepare  
3 Exhibit 6 according to my guidelines.  
4 Q. Okay. So someone at Analysis  
5 Group prepared Exhibit 6?  
6 MS. MCENROE: Objection to  
7 form.  
8 A. Someone at Analysis Group  
9 prepared Exhibit 6 under my guidelines. I  
10 like -- this is my report, so I don't want to  
11 say that someone else is -- I don't want to  
12 give credit to someone else for what is my  
13 report. Someone assisted me in developing  
14 Appendix B, which is Exhibit 6.  
15 BY MR. PIFKO:  
16 Q. Do you know who specifically at  
17 Analysis Group put the information into  
18 Exhibit 6?  
19 A. So Mr. Fink, Ms. VanSant would  
20 definitely have been involved, and one or two  
21 of the other analysts.  
22 The reason why is because there  
23 are multiple different reports that are  
24 culled through.

Page 147

1 Q. All right. So this has numbers  
2 on the left for each expert, correct?  
3 A. That is correct.  
4 Q. Do you know if -- there's 21 of  
5 them. Do you agree?  
6 A. I agree.  
7 Q. Do you know if all these  
8 experts provided a report?  
9 A. So from the exhibit it appears  
10 that all the experts provided a report. I'm  
11 not sure if all those reports have ultimately  
12 made it into the litigation. I understand  
13 that at various stages there were experts  
14 whose reports did not make it into the  
15 subsequent litigation. I don't know the  
16 legalese around it. But these are the  
17 reports that my team reviewed.  
18 Q. Okay. Do you know if there are  
19 any amendments to any of these reports?  
20 A. I am not aware of whether or  
21 not amendments were filed to these reports.  
22 Q. If there were amendments, do  
23 you know what version the team reviewed?  
24 MS. MCENROE: Objection to

Page 148

1 form.  
2 A. The -- I suspect that the  
3 versions that are reported here are the  
4 initial versions that were performed. As you  
5 can see here, the table is illustrating a few  
6 things, not a lot. What's the expert  
7 assignment? So to the extent that the  
8 assignment would have changed in an  
9 amendment, which I don't think it would have,  
10 that's a non-issue. The core opinion would  
11 have changed? I don't think it would have.  
12 That would be a non-issue. And whether Rite  
13 Aid was mentioned, I'm not aware of any  
14 changes in reports that now mention Rite Aid  
15 that had not previously mentioned Rite Aid.  
16 BY MR. PIFKO:  
17 Q. Okay. But you don't know  
18 either way whether the team reviewed any  
19 amendments?  
20 MS. MCENROE: Objection to  
21 form.  
22 A. I don't know whether or not the  
23 team reviewed amendments. But I -- if they  
24 were available, I would suspect so, but I

Page 149

1 cannot tell you for sure.  
2 BY MR. PIFKO:  
3 Q. Did you review all 21 of these  
4 reports?  
5 A. I reviewed in detail several of  
6 the reports, particularly ones that I had  
7 drawn in my -- in my own report. Some of the  
8 reports are not -- are somewhat orthogonal to  
9 what I'm talking about here, and so I didn't  
10 review those in detail.  
11 And I asked my team to go  
12 through the reports and identify whether or  
13 not there's any issues that I should be aware  
14 of as they relate to my assignment and as  
15 they relate to the core opinions that I  
16 wanted to make here.  
17 Q. Okay. So is your testimony  
18 that you reviewed all the reports to some  
19 degree?  
20 MS. MCENROE: Objection to  
21 form.  
22 A. My testimony would be that I  
23 reviewed all reports to some degree, but with  
24 much greater degree to the reports that are



Page 150

1 germane to mine.  
 2 For example, McCann's report I  
 3 read page to page multiple times because I  
 4 spent half of my report talking about his own  
 5 report.  
 6 BY MR. PIFKO:  
 7 Q. Okay. And let's just go  
 8 through them.  
 9 David Courtwright's report, did  
 10 you read that cover to cover?  
 11 A. No. The only report that I  
 12 would have read cover to cover would be  
 13 Mr. McCann's report.  
 14 Q. Okay. So you didn't --  
 15 A. And possibly Mr. -- Professor  
 16 Cutler's report as well, though that was a  
 17 little bit further back, and I only allude to  
 18 it very briefly in my own report.  
 19 Q. You said possibly David  
 20 Cutler's report. Did you -- do you know one  
 21 way or another if you reviewed it cover to  
 22 cover?  
 23 A. I reviewed the majority of  
 24 Mr. Cutler's report, and I reviewed the

Page 151

1 entirety of Mr. McCann's report, and I  
 2 directed my team to review in detail each one  
 3 of these reports.  
 4 Q. So we have this list of these  
 5 21 names. Do you know any of these  
 6 individuals professionally or personally?  
 7 A. Some of these individuals I  
 8 would know professionally.  
 9 Q. Okay. Which ones do you know  
 10 professionally?  
 11 A. So Number 3, Professor Caleb  
 12 Alexander; 4, Professor Cutler; 6,  
 13 Professor Gruber; 11, Professor McGuire; 13,  
 14 Professor Rosenthal. And I believe that's  
 15 it.  
 16 Q. Okay. Do you know any of these  
 17 people personally?  
 18 A. What do you mean by  
 19 "personally"?  
 20 Q. Well, like you know someone in  
 21 a professional capacity, maybe you interact  
 22 with them in a working manner, but maybe some  
 23 people you know them socially is what I'm  
 24 asking.

Page 152

1 A. No. So I can -- the  
 2 individuals -- several of these individuals  
 3 are at Harvard and MIT, so one of them is a  
 4 collaborator of mine on some work.  
 5 Q. Who is that?  
 6 A. That's Professor Gruber. We've  
 7 collaborated on projects. I wasn't aware  
 8 that he was involved in the opioid litigation  
 9 until an expert report was filed.  
 10 David Cutler is a professor at  
 11 Harvard.  
 12 Thomas McGuire is a professor  
 13 at Harvard.  
 14 And Meredith Rosenthal is a  
 15 professor at Harvard.  
 16 If I were to look back in my  
 17 social calendar in the last six months to a  
 18 year, I don't think I've had dinner with any  
 19 of these individuals. That would be one  
 20 proxy for your question.  
 21 Q. Caleb Alexander, you said you  
 22 know him professionally. How do you know  
 23 him?  
 24 A. I know him in a limited way. I

Page 153

1 think we had some overlap at the University  
 2 of Chicago. He's now at Johns Hopkins, and  
 3 he's been there many years. I probably saw  
 4 him last maybe six years ago, five or six  
 5 years.  
 6 Q. We talked about David Cutler.  
 7 You know him from Harvard?  
 8 A. Yes.  
 9 Q. Jonathan Gruber?  
 10 A. From MIT.  
 11 Q. You know him from when you were  
 12 an undergrad there?  
 13 A. No. I do not know him from  
 14 undergrad. I don't know if he was there when  
 15 I was an undergrad. He may not -- that was a  
 16 long time ago.  
 17 Q. Yeah. So that's what I was  
 18 just clarifying for the record.  
 19 So you know him because you --  
 20 because you're both in Boston, you interact  
 21 with him?  
 22 A. Exactly. These are all very  
 23 good health economists.  
 24 Q. Thomas McGuire?

Page 154

1 A. Also at Harvard.  
2 Q. And Meredith Rosenthal, same  
3 thing?  
4 A. Yes, also Harvard.  
5 (Whereupon, Jena Exhibit  
6 Number 7 was marked for  
7 identification.)  
8 BY MR. PIFKO:  
9 Q. Handing you what's marked as  
10 Exhibit 7. Take a minute to look at  
11 Exhibit 7. Let me know when you're done.  
12 A. I'm done.  
13 Q. Okay. Can you tell me what  
14 Exhibit 7 is?  
15 A. Sure. Exhibit 7 is Appendix C  
16 in my report. It reports Materials  
17 Considered.  
18 Q. This is a true and correct copy  
19 of all the materials considered?  
20 A. I believe so.  
21 Q. To your knowledge, there's  
22 nothing that you considered that's not in  
23 here?  
24 A. That's correct.

Page 155

1 Q. To your knowledge, is there  
2 anything that you didn't consider that's in  
3 here?  
4 A. No.  
5 Q. Partway through we have -- if  
6 you'd go to C-5. So C-5 through C-11 makes  
7 reference to documents in the litigation.  
8 A. Yes.  
9 Q. Let me know when you're there.  
10 A. I'm there.  
11 Q. Okay. How did you come to  
12 obtain these specific documents?  
13 A. My team had full access to the  
14 documents that are produced in litigation,  
15 again, as well as my other research and  
16 publicly available documents. And in forming  
17 my outline and in devising a strategy to  
18 thinking about the quality of anti-diversion  
19 at Rite Aid, as well as other related issues,  
20 I asked my team to search through documents  
21 specifically within Rite Aid, but also other  
22 places, to document exactly what are the  
23 different processes and structures that the  
24 organization, Mid-Atlantic distribution

Page 156

1 facility, as well as the headquarter, had in  
2 place to prevent the diversion of opioids.  
3 Q. And that's how this list was  
4 created?  
5 A. That is correct.  
6 Q. Do you know how the team  
7 obtained access to the documents?  
8 A. They had access to all the  
9 documents that have been produced in the  
10 litigation.  
11 Q. Okay. Do you know physically  
12 how they had that access?  
13 A. "Physically," can you clarify  
14 what you mean?  
15 Q. How did they gain access to all  
16 the documents in the litigation?  
17 A. How -- do you mean by computer  
18 or what --  
19 Q. Whatever --  
20 A. -- legal authority gave them  
21 that?  
22 Q. Whatever method they used.  
23 A. Oh, I would assume that most of  
24 it is electronic, and maybe through servers,

Page 157

1 maybe through disks. I'm not sure in each  
2 one of these cases how the specific document  
3 was obtained.  
4 Q. Okay. Did you personally  
5 review any of these documents?  
6 A. Yes, I have reviewed some of  
7 these documents.  
8 Q. Do you know which ones?  
9 A. If we went through my report,  
10 the specific documents that I call on in the  
11 report itself as opposed to in the materials  
12 considered, each one of those documents I  
13 would have -- I would have reviewed  
14 personally, as well as other documents that  
15 are in the materials considered that I may  
16 not have cited in the actual report itself.  
17 Q. How did you come to access the  
18 documents?  
19 A. I would access them through a  
20 computer provided to me as a PDF file.  
21 Q. Okay. So the team would send  
22 you a PDF of certain documents?  
23 A. That's correct.  
24 Q. Via e-mail or something?

<p style="text-align: right;">Page 158</p> <p>1 A. Not via e-mail. Usually  2 through a secure mechanism.  3 Q. Okay. Like an FTP exchange?  4 A. Something like that.  5 Q. So from time to time the team  6 would upload some documents for your  7 attention? Is that how it works?  8 A. From time to time they would do  9 that. And also in my report I have a zip  10 file, which is a compressed data file that's  11 probably more than 1 gigabyte, which links to  12 the exact documents that I rely on in my  13 report.  14 So, for instance, if I make a  15 comment and I want to refresh my memory, look  16 at what the underlying document is, I can  17 click on that link in my report, it takes me  18 to the underlying document and I can look at  19 the entire document so I can understand where  20 my particular statement in the report sits  21 and fits into the overall context of the  22 underlying document.  23 Q. So you have an electronic  24 version that's hyperlinked, basically, is</p>	<p style="text-align: right;">Page 160</p> <p>1 reviewed?  2 A. Sure. I can estimate. If we  3 want to do it in a thorough way, we'd have to  4 spend quite a bit of time with the report,  5 but Debra Chase, Keith Frost, Larry Ringgold,  6 Marian Wood, Janet Getzey Hart, Kyle Wright,  7 Thomas Prevoznik, Joseph Rannazzisi, Matthew  8 Perri. These are the ones that are  9 immediately coming to mind -- to my mind.  10 Q. Did you read those cover to  11 cover?  12 A. I did not read each one of  13 these depositions cover to cover, but I read  14 the portions that are relevant to my opinion,  15 because these are broad -- many of these are  16 broad fact depositions, and I read the  17 portions that are critical to my opinion.  18 Q. How did you determine which  19 portions were relevant to your opinion?  20 A. I directed my team to read  21 through the reports, in this case the  22 depositions, and asked them to identify the  23 places in the report where arguments or facts  24 were being stated that were critical to my</p>
<p style="text-align: right;">Page 159</p> <p>1 that what you're saying?  2 A. To -- not to the entire  3 materials considered, but to the things that  4 are cited in the report.  5 Q. Okay. So if something is cited  6 in the report, you can click on it, and then  7 it pulls up the actual document, is that what  8 you're saying?  9 A. That's correct.  10 Q. How about deposition  11 transcripts, did you personally review any  12 deposition transcripts?  13 A. I did.  14 Q. Do you know which ones?  15 A. I can look at them in the  16 report, but, in particular, Section 4  17 outlines a lot of deposition transcripts from  18 various Rite Aid employees, DEA employees,  19 Maryland State Board of Pharmacy documents.  20 So those are the places in the report where I  21 rely most heavily on deposition testimony.  22 Q. Looking at Exhibit 7, the first  23 page, it's got depositions. Can you tell me  24 which depositions that you personally</p>	<p style="text-align: right;">Page 161</p> <p>1 understanding of what are the structures and  2 processes that Rite Aid has in place to  3 prevent diversion of opioids.  4 Q. Go to Page C-4. Let me know  5 when you're there.  6 A. I'm there.  7 Q. Okay. See the section "Other  8 Court Documents"?  9 A. Yes.  10 Q. It's got -- the first two items  11 are legal citations. Do you know what those  12 are?  13 A. I believe one of them refers to  14 the Controlled Substances Act. I'd have to  15 flip through my report for the other one.  16 Unfortunately, I'm not a legal  17 scholar, so I don't even know what that  18 little squiggly sign means.  19 Q. Did you read the first one in  20 its entirety?  21 A. So I believe that that refers  22 to portions of the Controlled Substances Act.  23 I haven't read the document in its entirety,  24 but I did read the portions that are relevant</p>

<p style="text-align: right;">Page 162</p> <p>1 to my report.          2 Q. Okay.          3 A. And I'm also not a legal          4 scholar, so my ability to interpret it in a          5 legal way would be, not just limited, it          6 would be zero.          7 Q. Okay. And then my question is          8 how do you -- how did you determine which          9 portions were relevant to your report?          10 A. It's very clear, actually,          11 because I wanted to look at two things. One          12 is what does the Act state with respect to          13 the level of effective control that a          14 distributor should have under the CSA; and          15 then, secondly, what should be the          16 expectations required to the monitoring and          17 evaluation of orders that might be of          18 potentially unusual size or frequency or          19 pattern.          20 Q. Okay. How specifically did you          21 determine which sections were relevant to          22 that?          23 A. Those sections are pretty          24 straightforward. This is a case -- or at</p>	<p style="text-align: right;">Page 164</p> <p>1 A. I don't know if that's a          2 portion of the CSA or not. Again, I'm not a          3 legal scholar, so this documentation is a          4 little bit foreign to me.          5 I point you to Page 3 of my          6 report where I rely on this, and I say that          7 this -- this law was requiring that          8 distributors, quote/unquote, provide          9 effective controls and procedures to guard          10 against theft and diversion of controlled          11 substances.          12 My only point here is to say          13 that there appears to be -- I'm not a lawyer,          14 but there appears to be law about what          15 distributors should be doing in terms of          16 effective control and procedures to prevent          17 diversion, not just of opioids but of          18 controlled substances.          19 Q. These other two documents, the          20 third one, do you know what that is?          21 A. So this looks like -- I'm just          22 going to read it here, and then I'll describe          23 my understanding. The Second Supplemental          24 Objectives (sic) and Answers to Plaintiffs'</p>
<p style="text-align: right;">Page 163</p> <p>1 least my assignment was to look at whether or          2 not Rite Aid as a distributor -- or one of          3 the portions of my assignment was to look at          4 whether Rite Aid as a distributor had an          5 effective program for anti-diversion, one          6 component of which would be a suspicious          7 ordering monitoring program. The language in          8 the CSA simply states that that is something          9 that registrants should do.          10 So the portion of my report          11 that relies to it is only this point right          12 here, which is to say there's a regulatory          13 policy that organizations should be doing          14 this.          15 In my particular assignment, I          16 was asked to evaluate how was Rite Aid doing          17 it in this regard, along with other things in          18 the assignment.          19 Q. Okay. How about the second          20 document listed in Other Court Documents, do          21 you see that?          22 A. I do.          23 Q. Okay. Do you know what that          24 is?</p>	<p style="text-align: right;">Page 165</p> <p>1 First Set of Interrogatories. My -- again,          2 I'm not a legal scholar. My understanding of          3 this document, the way I relied on it is it          4 provides a summary as well as answers by          5 counsel representing Rite Aid which includes          6 direct material from -- I'm going to use the          7 word fact experts, not knowing better words,          8 from Rite Aid to describe various things that          9 it had in place.          10 So, for instance, in my own          11 report, primarily in Section 4 of the report,          12 I refer to specific Rite Aid employees who          13 describe what are the processes that were in          14 place. And a lot of that information is in          15 this Second Supplemental Objections and          16 Answers, for example, an auto-replenishment          17 system, thresholds for distributing opioids,          18 if you exceed it then you don't get the          19 opioids, the system of putting opioids and          20 other controlled substances in locked cages,          21 etcetera.          22 Q. How about the last item, do you          23 know what that is?          24 A. This one I don't recall.</p>



<p style="text-align: right;">Page 166</p> <p>1 (Whereupon, Jena Exhibit  2 Number 8 was marked for  3 identification.)  4 BY MR. PIFKO:  5 Q. Handing you what's marked as  6 Exhibit 8.  7 A. Thanks.  8 Q. Take a moment to review that,  9 and let me know when you're done.  10 A. I reviewed it.  11 Q. All right. Do you know what  12 that is?  13 A. This is my CV.  14 Q. Is this complete and accurate?  15 A. Yes, it is.  16 Q. Is it accurate as of today's  17 date?  18 A. Yes, it is.  19 Q. Is there any other work that  20 you have that you're engaged in that you need  21 to add to it?  22 A. No.  23 Q. Okay. We request that if you  24 do other updates to your CV, please provide</p>	<p style="text-align: right;">Page 168</p> <p>1 Q. Take a moment to review  2 Exhibit 9. Let me know when you're done.  3 A. I'm done.  4 Q. Exhibit 9 is another document  5 that was provided to me yesterday. Can you  6 tell me what Exhibit 9 is?  7 A. Sure. Exhibit 9, Page 1 says  8 "Dr. Anupam Babu Jena Professional Fees"  9 received.  10 So these hours and amount paid  11 reflect what we went through earlier with  12 respect to the invoices. This is the direct  13 payments that I received from Analysis Group  14 for the National Prescription Opioid  15 Litigation with Rite Aid for my professional  16 fees.  17 Q. The second page, do you know  18 what that reflects?  19 A. Yes. The second page refers to  20 something called attribution, so this is all  21 of the billings from Analysis Group to -- for  22 Rite Aid work that's exclusive of my  23 professional billing, that's not included  24 here, that's separate billing. So this is</p>
<p style="text-align: right;">Page 167</p> <p>1 to counsel an updated copy, okay?  2 MS. MCENROE: Objection. We  3 will take that request under  4 advisement and supplement our  5 disclosures as obligated under the  6 rules from time to time.  7 BY MR. PIFKO:  8 Q. Do you have different versions  9 of your CV for different types of work?  10 A. No.  11 Q. Like some people have one --  12 maybe like if you were seeking another  13 academic position, maybe you'd have one  14 version, versus if you're doing consulting  15 work you have another version.  16 A. No. This is my only CV.  17 Q. Okay.  18 (Whereupon, Jena Exhibit  19 Number 9 was marked for  20 identification.)  21 BY MR. PIFKO:  22 Q. Handing you what's marked as  23 Exhibit 9.  24 A. Thank you.</p>	<p style="text-align: right;">Page 169</p> <p>1 the work of the various names that you saw on  2 the invoices that we talked about earlier.  3 This is the billings to Rite Aid from  4 Analysis Group.  5 Q. Do you know what all these  6 columns represent?  7 A. Yes, I do.  8 Q. Okay. What does the "AG  9 Eligible Prof Fees" column represents?  10 A. So I believe that stands for  11 Analysis Group eligible professional fees.  12 So these would be the fees representing the  13 hours worked and the hourly rate of all of  14 the people that you saw on those invoices,  15 excluding me.  16 Q. Okay. So that -- that was  17 going to be one of my questions.  18 So that doesn't include the  19 numbers that are on Page 1 of Exhibit 9?  20 A. That's correct. Those are  21 separate.  22 Q. And then this only goes through  23 April, 2019, correct?  24 A. That is correct.</p>



Page 170

1 Q. So if we look back at  
2 Exhibit 3, we can see that -- go to the last  
3 bundle of Exhibit 3, which is dated May 21,  
4 2019. Let me know when you're there.

A. Yes, I see that.

Response	Percentage
U.S. should take action to reduce greenhouse gas emissions	95%
U.S. should not take action to reduce greenhouse gas emissions	5%

BY MR. PIFKO:

Q. Do you know anything about the number of hours or dollar amounts billed by Analysis Group in May?

A. I do not know what they billed in May.

Page 171

Q. How about in June leading up to the deposition?

A. In the last four days, no, I don't know.

(Whereupon, Jena Exhibit Number 10 was marked for identification.)

BY MR. PIFKO:

Q. Handing you what's marked as Exhibit 10. Take a minute to review that, and let me know when you're done.

(Witness reviewing document.)

A. Okay. I reviewed it.

Q. Okay. Have you seen this before?

A. I saw this just before I came into this room around 11:00 a.m.

Q. Okay. If you look to the last page of Exhibit 10, there's some categories of materials.

Do you see there?

A. The last page, yes, I see three bullet points.

Q. Looking closely at those, have

Page 172

you provided all those materials to counsel?

A. Yep. Yes. So all documents that I've reviewed since the date of my report, which is no other documents.

Itemization of hours spent, compensation paid, including all invoices, all of the invoices that I've submitted to Analysis Group, which is how I submit my invoices, have been submitted.

And the CV that you just presented me is the most current CV, and it's my only CV.

Page 173

A horizontal bar chart titled 'U.S. should take action to address climate change'. The y-axis lists age groups: 18-29, 30-49, 50-69, 70+, and 'All adults'. The x-axis represents the percentage of respondents, ranging from 0 to 100. For each age group, there are two bars: a blue bar for 'Men' and an orange bar for 'Women'. The data shows that in all age groups, a majority of respondents believe the U.S. should take action to address climate change. The percentage of respondents who believe in taking action is generally higher among younger age groups and among women compared to men.

Age Group	Men (%)	Women (%)
18-29	88	92
30-49	85	90
50-69	82	88
70+	78	85
All adults	80	85

**Q.** Is there anything, to your knowledge, inaccurate in your report?

A. No.

Q. We talked about testimony.

Have you ever -- aside from the -- like a lawsuit, have you ever testified before a government body?

A. I have never testified before a

Page 174

1 government body, no.  
2 Q. Have you ever testified before  
3 a grand jury proceeding?  
4 A. No.  
5 Q. Have you ever provided  
6 testimony to the FDA?  
7 A. Not to the FDA, no.  
8 Q. Maybe less formal than  
9 testimony, any statements or anything like  
10 that?  
11 A. No, no written statements to  
12 the FDA.  
13 Q. How about oral?  
14 A. No oral statements, no.  
15 Q. Okay. Have you ever done any  
16 advertising for your expert work?  
17 A. Advertising, no.  
18 Q. How about any advertising for  
19 consulting work?  
20 A. No.  
21 Q. When you were interacting with  
22 counsel on this matter, did they provide you  
23 with any assumptions to consider in  
24 connection with your opinion?

Page 175

1 A. No.  
2 Q. Did they provide you with any  
3 facts?  
4 A. Can you clarify? What do you  
5 mean by "facts"?  
6 Q. Did they communicate anything  
7 to you that they told you was a fact that you  
8 should be aware of in connection with the  
9 case?  
10 A. The only facts that I rely on  
11 in my report are the ones that my team  
12 identified from the record in the matter.  
13 Q. Okay. How about any data, did  
14 counsel provide you with any data that you  
15 used in forming your opinions?  
16 A. No. The only -- the data that  
17 we used is the ARCOS data.  
18 Q. Were there any other databases  
19 that your -- you or your team examined in  
20 forming your report beside the ARCOS data?  
21 A. No, just the ARCOS data. I  
22 mean, I rely on publicly available documents  
23 and studies, but those aren't databases,  
24 those are studies.

Page 176

1 MR. PIFKO: We can go off the  
2 record. I think I'm almost done here.  
3 MS. MCENROE: Take a little  
4 break.  
5 THE VIDEOGRAPHER: The time is  
6 2:44 p.m. We're off the record.  
7 (Whereupon, a recess was  
8 taken.)  
9 THE VIDEOGRAPHER: The time is  
10 2:49 p.m. We're on the record.  
11 BY MR. PIFKO:  
12 Q. Just one other question.  
13 Do you understand yourself to  
14 be only retained for the current bellwether  
15 case track, or all opioid cases for Rite Aid?  
16 MS. MCENROE: Objection to  
17 form.  
18 A. My understanding is I've been  
19 retained for this particular case.  
20 BY MR. PIFKO:  
21 Q. Okay. Just the Cuyahoga and  
22 Summit County cases?  
23 A. Yes.  
24 MR. PIFKO: Okay. So subject

Page 177

1 to any recross I may have based on  
2 questions from other people, I don't  
3 have any other further questions at  
4 this time.  
5 MS. MCENROE: I have just a  
6 very few brief questions.  
7 EXAMINATION  
8 BY MS. MCENROE:  
9 Q. Dr. Jena, nice to see you. As  
10 you know, my name is Elisa McEnroe, counsel  
11 for Rite Aid.  
12 You testified just a minute ago  
13 regarding the data that was considered in the  
14 forming of your opinions.  
15 Do you remember those lines of  
16 questioning?  
17 A. Yes.  
18 Q. And you referred exclusively to  
19 ARCOS data. Do you have any additions or  
20 corrections to that response?  
21 A. Yeah, I should be more clear.  
22 I used the ARCOS data for the analysis of  
23 Dr. McCann's methodology, suspicious order or  
24 flag methodology, and I used Rite Aid

<p style="text-align: right;">Page 178</p> <p>1 distribution data for the falsification test</p> <p>2 that we spoke about earlier looking at</p> <p>3 levothyroxine, metoprolol succinate, and the</p> <p>4 other falsification drugs.</p> <p>5 Q. As is reflected in Appendix E</p> <p>6 of your report that we were looking at</p> <p>7 earlier?</p> <p>8 A. That is correct.</p> <p>9 Q. And a little bit earlier this</p> <p>10 afternoon you were discussing certain of</p> <p>11 plaintiffs' experts who you know</p> <p>12 professionally.</p> <p>13 Do you remember that?</p> <p>14 A. Yes.</p> <p>15 Q. And you referred to certain of</p> <p>16 them and their being economists.</p> <p>17 Do you remember that?</p> <p>18 A. Yes.</p> <p>19 Q. Are you adopting any of their</p> <p>20 opinions in this case?</p> <p>21 A. No, I'm not.</p> <p>22 MS. MCENROE: I have no further</p> <p>23 questions.</p> <p>24 MR. PIFKO: All right. I don't</p>	<p style="text-align: right;">Page 180</p> <p>1 COMMONWEALTH OF MASSACHUSETTS )</p> <p>2 SUFFOLK, SS. )</p> <p>3 I, MAUREEN O'CONNOR POLLARD, RDR,</p> <p>4 RSA, and Notary Public in and for the</p> <p>5 Commonwealth of Massachusetts, do certify</p> <p>6 that on the 6th day of June, 2019, at 11:09</p> <p>7 o'clock, the person above-named was duly</p> <p>8 sworn to testify to the truth of their</p> <p>9 knowledge, and examined, and such examination</p> <p>10 reduced to typewriting under my direction,</p> <p>11 and is a true record of the testimony given</p> <p>12 by the witness. I further certify that I am</p> <p>13 neither attorney, related or employed by any</p> <p>14 of the parties to this action, and that I am</p> <p>15 not a relative or employee of any attorney</p> <p>16 employed by the parties hereto, or</p> <p>17 financially interested in the action.</p> <p>18 In witness whereof, I have</p> <p>19 hereunto set my hand this 6th day of June,</p> <p>20 2019.</p> <p>21 _____</p> <p>22 MAUREEN O'CONNOR POLLARD, NOTARY PUBLIC</p> <p>23 CSR #149108</p> <p>24</p>
<p style="text-align: right;">Page 179</p> <p>1 have anything else.</p> <p>2 MS. MCENROE: Anybody else?</p> <p>3 MR. GEISE: No questions.</p> <p>4 MS. MCENROE: On the phone?</p> <p>5 Great, then that concludes</p> <p>6 Dr. Jena's deposition. Thank you.</p> <p>7 THE VIDEOGRAPHER: The time is</p> <p>8 2:51 p.m. This deposition has</p> <p>9 concluded, and we are off the record.</p> <p>10 (Whereupon, the deposition was</p> <p>11 concluded.)</p> <p>12</p> <p>13</p> <p>14</p> <p>15</p> <p>16</p> <p>17</p> <p>18</p> <p>19</p> <p>20</p> <p>21</p> <p>22</p> <p>23</p> <p>24</p>	<p style="text-align: right;">Page 181</p> <p>1 INSTRUCTIONS TO WITNESS</p> <p>2</p> <p>3 Please read your deposition over</p> <p>4 carefully and make any necessary corrections.</p> <p>5 You should state the reason in the</p> <p>6 appropriate space on the errata sheet for any</p> <p>7 corrections that are made.</p> <p>8 After doing so, please sign the errata</p> <p>9 sheet and date it. It will be attached to</p> <p>10 your deposition.</p> <p>11 It is imperative that you return the</p> <p>12 original errata sheet to the deposing</p> <p>13 attorney within thirty (30) days of receipt</p> <p>14 of the deposition transcript by you. If you</p> <p>15 fail to do so, the deposition transcript may</p> <p>16 be deemed to be accurate and may be used in</p> <p>17 court.</p> <p>18</p> <p>19</p> <p>20</p> <p>21</p> <p>22</p> <p>23</p> <p>24</p>

Page 182

1           -----  
              E R R A T A  
2           -----  
3 PAGE LINE CHANGE  
4 \_\_\_\_\_  
5 REASON: \_\_\_\_\_  
6 \_\_\_\_\_  
7 REASON: \_\_\_\_\_  
8 \_\_\_\_\_  
9 REASON: \_\_\_\_\_  
10 \_\_\_\_\_  
11 REASON: \_\_\_\_\_  
12 \_\_\_\_\_  
13 REASON: \_\_\_\_\_  
14 \_\_\_\_\_  
15 REASON: \_\_\_\_\_  
16 \_\_\_\_\_  
17 REASON: \_\_\_\_\_  
18 \_\_\_\_\_  
19 REASON: \_\_\_\_\_  
20 \_\_\_\_\_  
21 REASON: \_\_\_\_\_  
22 \_\_\_\_\_  
23 \_\_\_\_\_  
24 \_\_\_\_\_

Page 184

1           LAWYER'S NOTES  
2 PAGE LINE  
3 \_\_\_\_\_  
4 \_\_\_\_\_  
5 \_\_\_\_\_  
6 \_\_\_\_\_  
7 \_\_\_\_\_  
8 \_\_\_\_\_  
9 \_\_\_\_\_  
10 \_\_\_\_\_  
11 \_\_\_\_\_  
12 \_\_\_\_\_  
13 \_\_\_\_\_  
14 \_\_\_\_\_  
15 \_\_\_\_\_  
16 \_\_\_\_\_  
17 \_\_\_\_\_  
18 \_\_\_\_\_  
19 \_\_\_\_\_  
20 \_\_\_\_\_  
21 \_\_\_\_\_  
22 \_\_\_\_\_  
23 \_\_\_\_\_  
24 \_\_\_\_\_

Page 183

1  
2           ACKNOWLEDGMENT OF DEPONENT  
3  
4       I, \_\_\_\_\_, do  
5 Hereby certify that I have read the foregoing  
6 pages, and that the same is a correct  
7 transcription of the answers given by me to  
8 the questions therein propounded, except for  
9 the corrections or changes in form or  
10 substance, if any, noted in the attached  
11 Errata Sheet.  
12  
13  
14  
15  
16  
17 WITNESS NAME           DATE  
18  
19  
20  
21  
22  
23  
24

Subscribed and sworn  
To before me this  
\_\_\_\_\_ day of \_\_\_\_\_, 20\_\_\_\_.

My commission expires: \_\_\_\_\_

\_\_\_\_\_  
Notary Public